```
dis hist

     (FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007)

     FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007
L1                STRUCTURE UPLOADED
L2             23 S L1 SSS SAM
L3            450 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007
L4              0 S L3 AND (GEM(A)DIFLUORO)
L5              0 S L3 AND DIFLUORO
L6              1 S L3 AND ZINC
L7              0 S L3 AND REFORMATSKY
L8             44 S L3 AND (PROCESS OR PREPARA?)
L9              2 S L8 AND CARBONYL
L10             0 S L8 AND (CARBONYL(W)ADDITION)
```

```
Connecting via Winsock to STN

LOGINID:
ssspta1623kxg

STNLOGON timed out


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS  4  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS  8  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS  9  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality
 NEWS 13  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 14  DEC 18   CA/CAplus patent kind codes updated
 NEWS 15  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS 16  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29   PHAR reloaded with new search and display fields
 NEWS 25  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

```
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JAN 2007  HIGHEST RN 918776-45-1
DICTIONARY FILE UPDATES:  29 JAN 2007  HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10522365-3.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 10:30:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       29 TO ITERATE

100.0% PROCESSED       29 ITERATIONS                                23 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           257 TO      903
PROJECTED ANSWERS:              173 TO      747

L2            23 SEA SSS SAM L1

=> d scan

L2   23 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   L-Tryptophan, N2-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-
     arginyl-L-tryptophyl-L-tyrosyl- (9CI)
SQL  4
MF   C45 H55 N9 O12

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]acetyl]amino]- (9CI)
MF C14 H24 N2 O9

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Phenylalanine, N2-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-arginyl-L-histidyl-L-prolyl- (9CI)
SQL 4
MF C34 H49 N9 O11

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l1 sss full
FULL SEARCH INITIATED 10:31:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 670 TO ITERATE

100.0% PROCESSED 670 ITERATIONS 450 ANSWERS
SEARCH TIME: 00.00.01

L3 450 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3 and (gem(a)difluoro)
            55 L3
          7960 GEM
          1962 GEMS
          9134 GEM
                 (GEM OR GEMS)
         14446 DIFLUORO
           122 GEM(A)DIFLUORO
L4           0 L3 AND (GEM(A)DIFLUORO)

=> s l3 and difluoro
            55 L3
         14446 DIFLUORO
L5           0 L3 AND DIFLUORO

=> s l3 and zinc
            55 L3
        613510 ZINC
           119 ZINCS
        613533 ZINC
                 (ZINC OR ZINCS)
L6           1 L3 AND ZINC

=> dis l6 bib abs hitstr

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:80195  CAPLUS
DN   140:128606
TI   Preparation of gem difluorinated glycoconjugates as potential antitumor,
     antiviral, hypoglycemic prodrug agents
IN   Quirion, Jean Charles; Pannecoucke, Xavier; D. Hooge, Francois; Marcotte,
     Stephane
PA   Institut National des Sciences Appliquees de Rouen INSA, Fr.
SO   Fr. Demande, 27 pp.
     CODEN: FRXXBL
DT   Patent
LA   French
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   FR 2842810           A1    20040130    FR 2002-9627            20020725
     FR 2842810           B1    20060127
     CA 2492940           A1    20040219    CA 2003-2492940         20030723
     WO 2004014928        A2    20040219    WO 2003-FR2330          20030723
     WO 2004014928        A3    20040401
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003274202        A1    20040225    AU 2003-274202          20030723
     EP 1525208           A2    20050427    EP 2003-758183          20030723
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003012917        A     20050705    BR 2003-12917           20030723
     CN 1671723           A     20050921    CN 2003-817770          20030723
     JP 2006508048        T     20060309    JP 2004-526949          20030723
     US 2006142206        A1    20060629    US 2005-522365          20050921
PRAI FR 2002-9627         A     20020725
```

WO 2003-FR2330 W 20030723
OS CASREACT 140:128606; MARPAT 140:128606
GI



I



II

AB Gem difluorinated glycoconjugates I, wherein R1 is an aldehyde, acid, ester, alkyl, hydroxy, amine, amide; R2 is H, free or protected function alc.; R3 is protecting group; Y is alkoxy, amine, thioalkyl, were prepared via condensation of lactone sugar with bromodifluoromethylcarboxylate in the presence of zinc or of a derivative lanthanide and used as antitumor, antiviral, hypoglycemic prodrug agents (no data). Thus, glycoconjugate II was prepared in 68 % yield via condensation of the corresponding sugar lactone with BrCF2CO2Et in presence of zinc.

IT 648904-18-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of gem difluorinated glycoconjugates via condensation of lactone sugar with bromodifluoromethylcarboxylate as potential antitumor, antiviral, and hypoglycemic prodrug agents)

RN 648904-18-1 CAPLUS

CN β-D-gluco-3-Octulopyranosonamide, 2-deoxy-2,2-difluoro-N-[(4-methoxyphenyl)methyl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l3 and reformatsky
55 L3
686 REFORMATSKY
L7 0 L3 AND REFORMATSKY

=> s l3 and (process or prepara?)
55 L3
2371787 PROCESS
1612126 PROCESSES
3540094 PROCESS

```
                (PROCESS OR PROCESSES)
        1596328 PREPARA?
        2778145 PREPN
         207393 PREPNS
        2934454 PREPN
                (PREPN OR PREPNS)
        3775663 PREPARA?
                (PREPARA? OR PREPN)
L8          44 L3 AND (PROCESS OR PREPARA?)

=> s l8 and carbonyl
         172495 CARBONYL
          27506 CARBONYLS
         180708 CARBONYL
                (CARBONYL OR CARBONYLS)
L9           2 L8 AND CARBONYL

=> dis l9 1-2 bib abs hitstr

L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2002:716289  CAPLUS
DN   137:232918
TI   Helicomimetics and stabilized LXXLL peptidomimetics
IN   Spatola, Arno F.; Leduc, Anne-Marie
PA   University of Louisville, USA
SO   PCT Int. Appl., 22 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2002072597         A2    20020919    WO 2002-US7093          20020311
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2005054770         A1    20050310    US 2004-471120          20040923
PRAI US 2001-274846P       P     20010309
     WO 2002-US7093        W     20020311
OS   MARPAT 137:232918
AB   A helicomimetic compound for stabilizing the α-helical structure of a
     protein fragment, which can serve as an agonist or antagonist of
     protein-protein interactions, comprises a compound of structure
     R1-(Xn)-D-Cys-Y-Y-L-Cys-(Xn)-R2 [R1 is H, an alkyl, aryl, acetyl, formyl,
     or other blocking or solubilizing group, such as a polyethylene glycol
     (PEG) or other polyether moiety, linked to the N-terminal nitrogen through
     a carbon-nitrogen bond; X is one or more natural or unnatural amino acids,
     linked together in a chain from 0 to n in length; Y is a natural or
     unnatural amino acid, usually of the L-configuration, and with two such
     amino acids that need not be identical, separating the pairs of cysteines to
     form an i to i + 3 type of disulfide bridged unit; R2 is OH, NH2, NHR, OR,
     or other blocking or solubilizing group, such as polyethylene glycol (PEG)
     or other polyether moiety, linked to the C-terminal carbonyl
     through an oxygen or carbon or nitrogen linkage, such as an amide group].
     The invention includes helix-stabilized compds. that contain the so-called
     NR Box found in a large number of Nuclear Receptor Coactivator Proteins.  The
     NR Box sequence, consisting of Leu-Xxx-Yyy-Leu-Leu within a longer
     peptide, is found in both coactivator proteins and also in certain nuclear
```

receptors. The Boc-based Merrifield solid-phase method was used to prepare linear and cyclic peptides, including H-Lys-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-Asp-Ser-Ser-OH (AML-I-89/2) and H-D-Lys-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-NH2 (AKG-I-28). Ki values are tabulated for the peptides against estrogen receptors (ER) alpha and beta. Short linear peptides that contain the LXXLL sequence, such as Leu-Asn-Gln-Leu-Leu, do not display any inhibitory activity with respect to the desired effect of inhibiting the binding of the estrogen receptors to the helical segment of coactivator proteins. Compds. that contain a D-Cys, L-Cys pairing are especially active with respect to binding inhibition.

IT 459844-33-8P, AML-I-31
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of α-helix stabilized LXXLL peptidomimetics)

RN 459844-33-8 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-manno-octonoyl)-L-leucyl-L-α-glutamyl-L-glutaminyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:13473 CAPLUS

DN 122:56357

TI On the synthesis of C-glycosyl compounds containing double bonds without the use of protecting groups

AU Wulff, Guenter; Clarkson, Guy

CS Inst. Org. Chem. Makromol. Chem., Heinrich-Heine Univ., Duesseldorf, 40225, Germany

SO Carbohydrate Research (1994), 257(1), 81-95
CODEN: CRBRAT; ISSN: 0008-6215

DT Journal

LA English

OS CASREACT 122:56357

GI



I

AB A new range of C-glycosyl compds. carrying double bonds have been

synthesized as potential monomers for the prepn. of polyvinyl-saccharides. The syntheses were performed without the use of protecting groups and mostly in water as solvent. The starting material was the easily accessible 5-β-D-glycopyranosyl-1,3-dimethylbarbituric acid sodium salt I (R = Na) (obtained from D-glucose and 1,3-dimethylbarbituric acid in water). The alkylation reaction of I (R = Na) at C-5 of the barbiturate moiety was studied in detail. It works well with benzylic bromides in Me2SO and with allylic or benzylic bromides by an ultrasound/phase transfer catalyst-promoted alkylation in water. The resulting 5,5-dialkylated barbiturates, e.g. I (R = CH2C6H4-R1, R1 = H, CH:CH2, CH2CH2Br; R = CH2CR2:CH2, R2 = H, Ph, CO2Me), undergo an unusually facile and specific cleavage of the barbituric ring, losing the c-2 carbonyl, to yield novel mols. with a diamide moiety.

IT 160055-68-5P 160055-69-6P 160055-70-9P
160055-71-0P 160055-72-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 160055-68-5 CAPLUS

CN Propanediamide, N,N'-dimethyl-2-(phenylmethyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-69-6 CAPLUS

CN Propanediamide, 2-[(4-ethenylphenyl)methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-70-9 CAPLUS

CN Propanediamide, 5-[[4-(2-bromoethyl)phenyl]methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-71-0 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-(2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-72-1 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-(2-phenyl-2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> s l8 and (carbonyl(w)addition)
        172495 CARBONYL
         27506 CARBONYLS
        180708 CARBONYL
                  (CARBONYL OR CARBONYLS)
        168126 ADDITION
         15548 ADDITIONS
        180911 ADDITION
```

```
                (ADDITION OR ADDITIONS)
        1567120 ADDN
          73526 ADDNS
        1613493 ADDN
                (ADDN OR ADDNS)
        1711112 ADDITION
                (ADDITION OR ADDN)
            579 CARBONYL(W)ADDITION
L10           0 L8 AND (CARBONYL(W)ADDITION)

=> dis l8 1-44 bib abs hitstr

L8   ANSWER 1 OF 44  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1034391  CAPLUS
DN   145:397538
TI   Carboxamides as inhibitors of TGF-β and their  preparation
     and use in the treatment of conditions associated with excessive
     TGF-β activity.
IN   Axon, Jonathan; Chakravarty, Sarvajit; Hart, Barry; Mcenroe, Glenn;
     Murphy, Alison; Pontius, Karen; Sheng, Daniel; Wang, Gina; Yellapregada,
     Shanti
PA   Scios Inc., USA
SO   PCT Int. Appl., 135pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2006105222         A2    20061005    WO 2006-US11509         20060327
     WO 2006105222         A3    20061228
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006281763         A1    20061214    US 2006-390980          20060327
PRAI US 2005-665095P       P     20050325
OS   MARPAT 145:397538
GI
```



I



II

AB Certain appropriately substituted forms of pyrimidine, of formula I, having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGF-β activity. Compds. of formula I wherein Ar is (un)substituted phenyl; Y and Z are independently H, halo, NO2, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted heteroalkyl, (un)substituted heteroalkenyl, etc.; R1 is (un)substituted (hetero)alkyl, (un)substituted (hetero)acyl, (un)substituted alkoxy, (un)substituted alkylamino, (un)substituted (hetero)aryl, etc.; R2 is H; NR1R2 may form (un)substituted piperidine, (un)substituted morpholine, (un)substituted piperazine, and (un)substituted pyrrolidine; W is halo NH2 and derivs., NO2, CN, CF3, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; m is 0 and 1; n is 0-3; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by cyclocondensation of Et 3-methylbutanoate with Et formate and 2-fluoro-5-chlorobenzamidine; the resulting 2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidin-4-one underwent chlorination to give 4-chloro-2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidine, which underwent amination with Me 4-aminonicotinate to give Me 4-[2-(5-chloro-2-fluorophenyl)-5-isopropylpyrimidin-4-yl]nicotinate, which underwent hydrolysis to give the corresponding nicotinic acid, which underwent amination with cyclopropylamine to give compound II. All the invention compds. were evaluated for their TGF-β inhibitory activity (data given).

IT 911700-03-3P 911700-04-4P 911700-06-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of carboxamides as inhibitors of TGF-β useful in treatment of conditions associated with excessive TGF-β activity)

RN 911700-03-3 CAPLUS

CN D-gluco-Octonamide, 3,7-anhydro-N-[3-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]propyl]-2-deoxy-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911700-04-4 CAPLUS
CN D-gluco-Octonamide, 3,7-anhydro-N-[2-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]ethyl]-2-deoxy-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911700-06-6 CAPLUS
CN D-gluco-Octonamide, 3,7-anhydro-N-[3-[[[4-[[2-(5-chloro-2-fluorophenyl)-5-methoxy-4-pyrimidinyl]amino]-3-pyridinyl]carbonyl]amino]propyl]-2-deoxy-N-(1-methylethyl)-, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:548991 CAPLUS
DN 145:211327
TI Synthesis of a galacto-configured C-ketoside-based γ-sugar-amino acid and its use in peptide coupling reactions
AU Schweizer, Frank; Hindsgaul, Ole
CS Department of Chemistry, University of Manitoba, Winnipeg, MB, R3T 2N2, Can.
SO Carbohydrate Research (2006), 341(10), 1730-1736
CODEN: CRBRAT; ISSN: 0008-6215
PB Elsevier B.V.
DT Journal
LA English
AB γ-Sugar-amino acid analogs in the form of C-ketosides can be prepared in 5-6 steps starting from D-galactono-1,5-lactone. The key step in the synthesis is the trimethylsilyl trifluoromethanesulfonate (TMSOTf) promoted C-glycosylation of 2-deoxy-3-ulopyranosonates with trimethylsilyl cyanide. Hydrogenation of the resulting β-cyano esters provides C-ketoside-based γ-sugar-amino acids that serve as building blocks for the synthesis of unnatural neoglycopeptides.
IT 903882-01-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of a galacto-configured C-ketoside-based γ-sugar-amino acid and its use in peptide coupling reactions)
RN 903882-01-9 CAPLUS
CN L-Alanine, N-[3,7-anhydro-2-deoxy-3-C-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-D-glycero-L-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 903882-02-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of a galacto-configured C-ketoside-based γ-sugar-amino acid and its use in peptide coupling reactions)
RN 903882-02-0 CAPLUS
CN L-Alanine, N-[3,7-anhydro-2-deoxy-3-C-[[[(2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]methyl]-D-glycero-L-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:538719 CAPLUS
DN 145:46272
TI Preparation of gem-difluorinated C-glycopeptides and their use for the preservation of biological materials and/or in cryosurgery
IN Quirion, Jean-Charles; Castelot-Deliencourt- Godefroy, Geraldine
PA Institut National Des Sciences Appliquees De Rouen, Fr.
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006059227	A1	20060608	WO 2005-IB3940	20051202
WO 2006059227	B1	20061102		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

FR 2878851	A1	20060609	FR 2004-12782	20041202
PRAI FR 2004-12782	A	20041202		

OS MARPAT 145:46272
GI



I

AB The invention relates to gem-difluorinated C-glycopeptides R4(NHCHR1CONHCHR2CONHCHR3CO)1-5R5 [R4 is H, AA1, AA1-AA2 and R5 is OH, AA1, AA1-AA2, where AA1 and AA2 are independent and represent amino acids with a non-functionalized side chain; R1, R2, R3 are independently H, Me, PhCH2, Me2CH, Me2CHCH2, EtCHMe and one of R1-R3 is 2-tetrahydropyranyl-CF2CONH(CH2)3-4 in which 2-tetrahydropyranyl is substituted by 5-Y, 4-Y' (H, OH, PhCH2O, N3, amino, mercapto, etc.), 6-R6 (H, Me, CH2OH, CH2-glycoside group, protected hydroxymethyl), 3-R7 (OH, NH2, N3, OH, NH2 or protected hydroxy or amino), 1-RB (H, OH or protected hydroxy)] for use in the preservation of biol. materials and in cryosurgery. Thus, glycopeptide I was prepared by a multistep sequence starting from Me D-galactopyranoside and studied for its effect on the preservation of HEK 293 kidney cells and blood platelets.

IT 890015-62-0P 890015-70-0P
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of gem-difluorinated C-glycopeptides for preservation of biol. materials and/or in cryosurgery)

RN 890015-62-0 CAPLUS

CN L-Alanine, N6-(2-deoxy-2,2-difluoro-α-D-galacto-3-octulopyranosonoyl)-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 890015-70-0 CAPLUS
CN L-Alanine, N6-(2-deoxy-2,2-difluoro-α-D-galacto-3-octulopyranosonoyl)-L-lysyl-L-alanyl-L-alanyl-N6-(2-deoxy-2,2-difluoro-α-D-galacto-3-octulopyranosonoyl)-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl



IT 890015-56-2P 890015-57-3P 890015-58-4P
890015-60-8P 890015-61-9P 890015-66-4P
890015-68-6P 890015-69-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of gem-difluorinated C-glycopeptides for preservation of biol. materials and/or in cryosurgery)

RN 890015-56-2 CAPLUS

CN L-Lysine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890015-57-3 CAPLUS

CN L-Lysine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890015-58-4 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890015-60-8 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 890015-59-5
CMF C49 H60 F2 N4 O11

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 890015-61-9 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 890015-66-4 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-alanyl-L-alanyl-N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 890015-68-6 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-L-alanyl-N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, methyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 890015-67-5
CMF C97 H116 F4 N8 O21

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 890015-69-7 CAPLUS
CN L-Alanine, N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-L-alanyl-N6-[2-deoxy-2,2-difluoro-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-L-lysyl-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1314244 CAPLUS
DN 144:51830
TI Synthesis of metabolically stable analgesics, pain medications and other agents
IN Cashman, John R.; Macdougall, James M.
PA Human Biomolecular Research Institute, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005117589	A1	20051215	WO 2005-US19000	20050531
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
PRAI US 2004-575451P P 20040528
OS MARPAT 144:51830
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are analgesic-related compns. ABC [A = analgesic, opiate or derivative; B = linking group (e.g. S, NHC(:O)(CH2)n; n = 0 - 5); C = (un)substituted aryl, heteroaryl, saccharide {e.g., Z ; R8 = H, (C1-5-alkyl)C(:O), (C7-10-aralkyl)C(:O), C7-10-aralkyl, C1-5-alkyl, C6-12-aryl, (C6-12-aryl)C(:O); R9 = CH2OH, CH2O(C1-5-alkyl), CH2O2C(C1-5-alkyl), CH2O(C6-12-aryl), CO2H, CO2(C1-5-alkyl), CO2(C6-12-aryl), CO2(C7-10-aralkyl)}] and methods of using the compns. for modulation of analgesic receptor activity. Analgesics I [R1 = H, (C1-5-alkyl)C(:O), (C7-10-aralkyl)C(:O), C7-10-aralkyl, C1-5-alkyl, C6-12-aryl, (C6-12-aryl)C(:O), silyl; R2 = C1-5-alkyl, C3-6-cycloalkyl, (C3-6-cycloalkyl)alkyl, (C5-7-cycloalkenyl)alkyl, C6-12-aryl, C7-12-aralkyl, C6-12-heteroaryl, C7-12-heteroaralkyl, C2-5-alkenyl, C2-5-alkynyl (each optionally substituted with halogen, C1-5-alkoxy, NO2, CO2R); R3 = H, OH, R4 = H; R5 = H; R6 = YR7; R5R6 = heteroaryl; R7 = (un)substituted aryl, heteroaryl, saccharide; R = H, C1-5-alkyl; Y = S, NHC(:O)(CH2)n] are selected from alkaloids naltrexone, phenylpiperidine, piperidinol, prodine, piperidylpropionanilide, isoprodine, prodilidine, benzomorphan, morphan, azabicyclane, morphinan, [(diphenylamnio)ethyl]propionate, methadone, isomethadone, propoxyphene, dextromethorphan, benzazocin-8-ol, norbinaltrophine, naltrindole, guanidinylnaltrindole. Thus, morphine thioglycoside II was prepared from morphine 6-O-tosylate via thioglycosylation with Me [2,3,4-tri-O-acetyl-β-D-glucopyranosyluronate]-1-thiol in DMF containing NaH followed by saponification The compns. and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling. The analgesic activity of II was determined [Ki = 8.73 nM vs. μ opioid receptor; Ki = 31.4 nM vs. δ opioid receptor; Ki = 288 nM vs. κ opioid receptor; EC50 = 33.7 nM for stimulation of [35S]GTPγS binding at μ opioid receptor; EC50 = 50.13 nM for stimulation of [35S]GTPγS binding at δ opioid receptor].

IT 851217-50-0P 871119-49-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and desilylation of; synthesis of metabolically stable analgesics, pain medications and related agents)

RN 851217-50-0 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5α,6β)-7,8-didehydro-4,5-epoxy-17-methyl-3-[[tris(1-methylethyl)silyl]oxy]morphinan-6-yl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-49-2 CAPLUS
CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[(5α,6β)-7,8-didehydro-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,5-epoxy-17-methylmorphinan-6-yl]amino]-8-oxo-, methyl ester, 3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851217-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrogenation/debenzylation of; synthesis of metabolically stable analgesics, pain medications and related agents)
RN 851217-51-1 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5α,6β)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 871119-51-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. and saponification of; synthesis of metabolically stable analgesics, pain medications and related agents)
RN 871119-51-6 CAPLUS
CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[(5α,6β)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]amino]-8-oxo-, methyl ester, 3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 871119-68-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn., hydrogenolytic debenzylation and receptor binding of; synthesis of metabolically stable analgesics, pain medications and related agents)
RN 871119-68-5 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-N-[(5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 871119-58-3P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn., saponification and opioid antagonistic of; synthesis of metabolically stable analgesics, pain medications and related agents)
RN 871119-58-3 CAPLUS
CN L-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[(5α,6β)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-

6-yl]amino]-8-oxo-, methyl ester, 3,4,5-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851217-54-4P 871119-52-7P 871119-61-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of metabolically stable analgesics, pain medications and related agents)
RN 851217-54-4 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5α,6β)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-52-7 CAPLUS
CN D-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[(5α,6β)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]amino]-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-61-8 CAPLUS
CN D-glycero-L-gulo-Octonic acid, 2,6-anhydro-7,8-dideoxy-8-[[(5α,6β)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-yl]amino]-8-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851217-52-2P 871119-69-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of metabolically stable analgesics, pain medications and related agents)

RN 851217-52-2 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-deoxy-N-[(5α,6β)-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871119-69-6 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-N-[(5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:386328 CAPLUS
DN 143:406117
TI Antifreeze glycoprotein analogs: Synthesis, in vitro testing, and applications
AU Bouvet, Vincent; Ben, Robert N.
CS Department of Chemistry, D'Iorio Hall, University of Ottawa, Ottawa, ON, K1N 6N5, Can.
SO ACS Symposium Series (2005), 896(Glycomimetics), 151-166
CODEN: ACSMC8; ISSN: 0097-6156
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:406117
AB A series of first generation C-linked antifreeze glycoprotein (AFGP) analogs have been successfully prepared using conventional solid phase chemical These glycoconjugates range in mol. weight between 1.5 to 4.1 Kda and can be prepared using traditional linear solid phase protocol. Unlike the native system, the C-linked analogs possess enhanced chemical and biol. stability and consequently are well-suited for many potential medical, industrial and com. applications. Despite dramatic structural modifications (relative to the native system), several of these first generation analogs display significant antifreeze protein-specific activity.
IT 255851-86-6P 592532-44-0P
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and in vitro testing of glycopeptides as analogs of antifreeze glycoproteins)
RN 255851-86-6 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 592532-44-0 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









PAGE 2-A

PAGE 2-B



PAGE 2-C



PAGE 2-D

IT 255851-83-3P 255851-84-4P 592532-40-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and in vitro testing of glycopeptides as analogs of antifreeze glycoproteins)

RN 255851-83-3 CAPLUS

CN Glycine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 255851-84-4 CAPLUS
CN Glycine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 592532-40-6 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:137046 CAPLUS
DN 142:374105
TI Access to unnatural glycosyl amino acid building blocks via a one-pot Ritter reaction
AU Penner, Marlin; Taylor, David; Desautels, Danielle; Marat, Kirk; Schweizer, Frank
CS Department of Chemistry, University of Manitoba, Winnipeg, MB, R3T 2N2, Can.
SO Synlett (2005), (2), 212-216
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 142:374105
AB α-D-Galacto-2-deoxy-oct-3-ulopyranosonic acids, α-D-gluco-2-deoxy-oct-3-ulopyranosonic acids and α-L-galacto-2,8-dideoxy-oct-3-ulopyranosonic acids can be converted into unnatural glycosyl amino acids via a one-pot intramol. Ritter reaction. Initially, a ketopyranoside-based acid condenses under Lewis acid-promoted conditions with a nitrile (benzonitrile or acetonitrile) and a partially protected diamino ester (Boc-DAB-Ot-Bu, Boc-Orn-Ot-Bu) to form unnatural glycosyl amino esters. The resulting glycosyl amino esters are useful building blocks for solid-phase glycopeptide synthesis. For example, the glycosyl amino acid derived by condensation of α-D-galacto-2-deoxy-oct-3-ulopyranosonic acid with benzonitrile and DAB was used to replace serine in the potent opioid peptide sequence H2N-Tyr-D-Thr-Gly-Phe-Leu-Ser-CONH2.
IT 849472-56-6P 849472-65-7P 849472-72-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of glycosyl amino acids via one-pot Ritter reaction of ketopyranoside-based acid with benzonitrile or acetonitrile for solid phase glycopeptide synthesis)
RN 849472-56-6 CAPLUS
CN Butanoic acid, 4-[[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-65-7 CAPLUS
CN Butanoic acid, 2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-[[4,5,6,8-tetra-O-acetyl-3-(benzoylamino)-2,3-dideoxy-α-D-galacto-3-octulopyranosonoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-72-6 CAPLUS
CN Butanoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-[[4,5,6,8-tetra-O-acetyl-3-(benzoylamino)-2,3-dideoxy-α-D-galacto-3-octulopyranosonoyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 849472-57-7P 849472-58-8P 849472-59-9P
849472-60-2P 849472-61-3P 849472-64-6P
849472-66-8P 849472-68-0P 849472-69-1P
849472-70-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of glycosyl amino acids via one-pot Ritter reaction of ketopyranoside-based acid with benzonitrile or acetonitrile for solid phase glycopeptide synthesis)
RN 849472-57-7 CAPLUS
CN L-Ornithine, N5-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-58-8 CAPLUS
CN L-Ornithine, N5-[3-(acetylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-59-9 CAPLUS
CN Butanoic acid, 4-[[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-gluco-3-octulopyranosonoyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-60-2 CAPLUS
CN L-Ornithine, N5-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-gluco-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-61-3 CAPLUS
CN L-Ornithine, N5-[3-(acetylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-gluco-3-octulopyranosonoyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-64-6 CAPLUS
CN L-Alanine, N-[3-(benzoylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-66-8 CAPLUS
CN Butanamide, L-tyrosyl-D-threonylglycyl-L-phenylalanyl-L-leucyl-2-amino-4-[[3-(benzoylamino)-2,3-dideoxy-α-D-galacto-3-octulopyranosonoyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 849472-68-0 CAPLUS
CN Carbamic acid, [3-[[2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-propyl-α-D-galacto-3-octulopyranosonamidosyl]amino]-3-oxopropyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-69-1 CAPLUS
CN β-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-3-amino-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849472-70-4 CAPLUS
CN α-D-gluco-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:837270 CAPLUS
DN 141:337274
TI Cosmetic use of new desquamative agents
IN Dalko, Maria; Cavezza, Alexandre; Bernard, Dominique
PA L'oreal, Fr.
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1466590	A1	20041013	EP 2004-290756	20040322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	FR 2853540	A1	20041015	FR 2003-4349	20030408
	FR 2853540	B1	20060707		
	US 2005002889	A1	20050106	US 2004-813056	20040331

	JP 2004307508	A	20041104	JP 2004-113511	20040407
	JP 3808082	B2	20060809		
PRAI	FR 2003-4349	A	20030408		
	US 2003-471725P	P	20030520		

OS MARPAT 141:337274

GI



I

AB Cosmetic compns. containing I are used for topical used on hair or skin to prevent aging and improve the color of the skin and dry skin. Thus, 2-benzyl-N,N'-dimethyl-2-(3,4,5-trihydroxy-6-methyltetrahydropyran-2-yl)-malonamide was prepared and its efficacy in separating corneocytes from stratum corneum was shown. Formulation of an anti-acne gel is containing 3.0% active compound was disclosed.

IT 769140-43-4P
RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cosmetic use of new desquamative agents)

RN 769140-43-4 CAPLUS

CN Propanediamide, 2-β-D-glucopyranosyl-N,N'-dimethyl-2-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:536729 CAPLUS

DN 141:225760

TI Preparation of an advanced intermediate for the synthesis of stable analogs of guanofosfocin

AU George, Tesmol G.; Szolcsanyi, Peter; Koenig, Stefan G.; Paterson, Duncan E.; Isshiki, Yoshiaki; Vasella, Andrea

CS Laboratorium fuer Organische Chemie, ETH-Hoenggerberg, Zurich, CH-8093, Switz.

SO Helvetica Chimica Acta (2004), 87(5), 1287-1298
CODEN: HCACAV; ISSN: 0018-019X

PB Verlag Helvetica Chimica Acta

DT Journal

LA English

OS CASREACT 141:225760

GI



I

AB The synthesis of a C-mannosyl-guanosine, I, an advanced intermediate for the prepn. of stable analogs of guanofosfocin, is described. This convergent approach features an improved Traube-type synthesis of a 8-substituted guanine, followed by ribosylation. NMR Studies show that the C-mannopyranosyl moiety of I adopts a distorted 1C4 conformation while the nucleoside is predominantly syn-oriented.

IT 745822-38-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of a C-mannosyl-guanosine analog via Traube-type synthesis of the 8-substituted guanine followed by ribosylation)

RN 745822-38-2 CAPLUS

CN D-glycero-D-talo-Octonamide, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-3,7-anhydro-2-deoxy-4,6,8-tris-O-(phenylmethyl)-, 5-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:252533 CAPLUS
DN 140:287715
TI Preparation of modified peptide nucleic acid (PNA) prodrugs
IN Rasmussen, Palle; Frandsen, Niels Montano; Nyborg, Marlene; Rasmussen, Frank Winther; Hamzavi, Ramin; Nielsen, Peter Eigild; Kjaerulff, Soren
PA Santaris Pharma A/s, Den.
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024757	A2	20040325	WO 2003-DK588	20030911
	WO 2004024757	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2498772	A1	20040325	CA 2003-2498772	20030911
	AU 2003260289	A1	20040430	AU 2003-260289	20030911
	EP 1543019	A2	20050622	EP 2003-794821	20030911

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI	DK 2002-1334	A	20020911
	DK 2002-1786	A	20021119
	DK 2002-1956	A	20021220
	DK 2003-600	A	20030416
	WO 2003-DK588	W	20030911

OS MARPAT 140:287715

AB The invention relates to peptide nucleic acid (PNA) drugs, which are optionally modified in order to obtain novel PNA mols. with cell-specific delivery. PNA monomers RNHCHR1CHR2N(COCH2-B)CHR3CO2H [B is a naturally-occurring nucleobase (preferably A, T, G, or C) or a non-naturally-occurring nucleobase; R is H or a protecting group; R1, R2, R3 are H, an amino acid side chain, substituted alkyl, etc.] are claimed. The examples describe of PNAs, e.g., [GalNAc(OH)3]2-Lys-Gly-CATCACTGGCAGACCCTG-NH2, and PNA conjugates. A table shows the effect of GalNAc ligands on PNA delivery to the liver.

IT 675600-89-2P 675600-90-5P 675600-92-7P
675600-93-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of modified peptide nucleic acid (PNA) prodrugs)

RN 675600-89-2 CAPLUS

CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675600-90-5 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675600-92-7 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675600-93-8 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 675601-12-4P 675601-13-5P 675601-14-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of modified peptide nucleic acid (PNA) prodrugs)
RN 675601-12-4 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675601-13-5 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675601-14-6 CAPLUS
CN L-Lysine, N2-[2-[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl][(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:80195 CAPLUS
DN 140:128606
TI Preparation of gem difluorinated glycoconjugates as potential antitumor, antiviral, hypoglycemic prodrug agents
IN Quirion, Jean Charles; Pannecoucke, Xavier; D. Hooge, Francois; Marcotte, Stephane
PA Institut National des Sciences Appliquees de Rouen INSA, Fr.
SO Fr. Demande, 27 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2842810	A1	20040130	FR 2002-9627	20020725
	FR 2842810	B1	20060127		
	CA 2492940	A1	20040219	CA 2003-2492940	20030723
	WO 2004014928	A2	20040219	WO 2003-FR2330	20030723
	WO 2004014928	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274202	A1	20040225	AU 2003-274202	20030723
	EP 1525208	A2	20050427	EP 2003-758183	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012917	A	20050705	BR 2003-12917	20030723
	CN 1671723	A	20050921	CN 2003-817770	20030723
	JP 2006508048	T	20060309	JP 2004-526949	20030723
	US 2006142206	A1	20060629	US 2005-522365	20050921
PRAI	FR 2002-9627	A	20020725		
	WO 2003-FR2330	W	20030723		

OS CASREACT 140:128606; MARPAT 140:128606

GI



I



II

AB Gem difluorinated glycoconjugates I, wherein R1 is an aldehyde, acid, ester, alkyl, hydroxy, amine, amide; R2 is H, free or protected function alc.; R3 is protecting group; Y is alkoxy, amine, thioalkyl, were prepared via condensation of lactone sugar with bromodifluoromethylcarboxylate in the presence of zinc or of a derivative lanthanide and used as antitumor, antiviral, hypoglycemic prodrug agents (no data). Thus, glycoconjugate II was prepared in 68 % yield via condensation of the corresponding sugar lactone with BrCF2CO2Et in presence of zinc.

IT 648904-18-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of gem difluorinated glycoconjugates via condensation of lactone sugar with bromodifluoromethylcarboxylate as potential antitumor, antiviral, and hypoglycemic prodrug agents)

RN 648904-18-1 CAPLUS

CN β-D-gluco-3-Octulopyranosonamide, 2-deoxy-2,2-difluoro-N-[(4-methoxyphenyl)methyl]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:901818 CAPLUS
DN 140:199515
TI Carbohydrate-protein interactions at interfaces: comparison of the binding of Ricinus communis lectin to two series of synthetic glycolipids using surface plasmon resonance studies
AU Critchley, P.; Clarkson, G. J.
CS Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
SO Organic & Biomolecular Chemistry (2003), 1(23), 4148-4159
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 140:199515
AB Two C-lactosyl lipids and the related C-galactosyl lipids have been synthesized and their binding to RCA120 plant lectin was compared with a second series of thiolactosylethoxyalkanes. The interactions were measured quant. in real time by surface plasmon resonance (BIAcore) at a range of concns. and temps. from 5 to 30 °C. The C-galactosyl lipid (1,3-dimethyl-5-[β-d-galactopyranosyl]-5-(4-octadecyloxybenzyl)pyrimidine-2,4,6-trione) bound much more weakly with a KA = 8.86 + 105 than the corresponding C-lactosyl lipid (1,3-dimethyl-5-[β-d-galactopyranosyl-(1 4)-β-d-glucopyranosyl]-5-(4-octadecyloxybenzyl)pyrimidine-2,4,6-trione) (KA = 2.31 + 107). The influence of the linker region of the two different series of lactosyl lipids was clearly demonstrated by the differences in the binding to RCA120 lectin. The changes in kinetic values and in the enthalpic and entropic contribution to the free energy of binding reflected the importance of the linker and the hydrocarbon anchor holding the synthetic glycolipids in the neomembrane.
IT 660850-45-3P 660850-46-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(comparison of the binding of Ricinus communis lectin to synthetic glycolipids using surface plasmon resonance studies)
RN 660850-45-3 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]-2-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 660850-46-4 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]-2-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 660850-39-5P 660850-40-8P
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(prepn., acetylation and binding kinetics of; comparison of the binding of Ricinus communis lectin to synthetic glycolipids using surface plasmon resonance studies)
RN 660850-39-5 CAPLUS
CN Propanediamide, 2-β-D-galactopyranosyl-N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 660850-40-8 CAPLUS
CN Propanediamide, 2-(4-O-β-D-galactopyranosyl-β-D-glucopyranosyl)-N,N'-dimethyl-2-[[4-(octadecyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:737362 CAPLUS
DN 139:261505
TI Preparation of phosphotetrahydropyran monosaccharide phosphates as antiinflammatory agents and in treating diseases dependent on T-lymphocyte migration
IN Cowden, William Butler; Eschler, Bart Michael; March, Darren Ray; Francis, Douglas John; Gerba, Sendaba; Bartell, Gavin James; Charlton, Brett
PA Pharmaxis Pty Ltd., Australia
SO U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of Appl. No. PCT/AU01/00831.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003176363	A1	20030918	US 2003-338679	20030109
	US 6878690	B2	20050412		
	WO 2002004472	A1	20020117	WO 2001-AU831	20010711

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI AU 2000-8723 A 20000711
WO 2001-AU831 A2 20010711
OS MARPAT 139:261505
GI



AB The present invention provides phosphotetrahydropyran compds. I, wherein R is axial or equatorial and is selected from the group consisting of: alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, hydroxy-tetrahydro-pyranyloxyalkyl, (CH2)nCH2OR", (CH2)nCONHR", (CH2)nCH2NHR" and (CH2)nCOX, wherein n represents an integer from 0 to 20 inclusive; R" is selected from the group consisting of H, alkyl, aryl and acyl; and X is selected from the group consisting of Y, OY' and NY"Y'" wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and carbohydrate; Y' is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and carbohydrate; and Y" and Y'" are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl; wherein each of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl may be optionally substituted; provided that R is not Me, and the use thereof in treating diseases or conditions that are dependent on T-lymphocyte migration, as well as compns. containing said compds. Wherein the disease or condition is rheumatoid arthritis, multiple sclerosis, acute disseminated encephalomyelitis, psoriasis, Crohn's disease, T cell-mediated dermatitis, stromal keratitis, uveitis, thyroiditis, sialitis or type I diabetes. Thus, 3-phenyl-2-[2-(3,4,5-trihydroxy-6-phosphonooxymethyl-tetrahydro-pyran-2-yl)-acetylamino]-propionic acid monosodium salt was prepared and tested at a dose of 62 mg/kg/day s.c., on passively transferred autoimmune encephalomyelitis (EAE) in Lewis rats.

IT 388593-58-6P 388593-75-7P 388593-81-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phosphotetrahydropyran monosaccharide phosphates as antiinflammatory agents and in treating diseases dependent on tlymphocyte migration)

RN 388593-58-6 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 388593-75-7 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

RN 388593-81-5 CAPLUS
CN D-manno-Octonamide, 3,7-anhydro-2-deoxy-N-(2-phenylethyl)-, 8-(dihydrogen phosphate), monosodium salt, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 388593-61-1P 388593-62-2P 388593-64-4P
388593-78-0P 388593-79-1P 388593-80-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of phosphotetrahydropyran monosaccharide phosphates as antiinflammatory agents and in treating diseases dependent on tlymphocyte migration)

RN 388593-61-1 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-62-2 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-64-4 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-78-0 CAPLUS

CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-manno-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-79-1 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-phosphono-D-manno-octonoyl]-, 1,5-[bis(phenylmethyl)] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-80-4 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:679388 CAPLUS
DN 139:381726
TI Modulation of the Pharmacokinetic Properties of PNA: Preparation of Galactosyl, Mannosyl, Fucosyl, N-Acetylgalactosaminyl, and N-Acetylglucosaminyl Derivatives of Aminoethylglycine Peptide Nucleic Acid Monomers and Their Incorporation into PNA Oligomers
AU Hamzavi, Ramin; Dolle, Frederic; Tavitian, Bertrand; Dahl, Otto; Nielsen, Peter E.
CS Center for Biomolecular Recognition, Department of Medical Biochemistry

and Genetics, University of Copenhagen, Copenhagen, DK-2200, Den.

SO Bioconjugate Chemistry (2003), 14(5), 941-954
CODEN: BCCHES; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
OS CASREACT 139:381726

GI



I

AB A series of N-(2-aminoethyl)-α-amino acid thymine peptide nucleic acid (PNA) monomers bearing glycosylated side chains in the α-amino acid position (e.g, I) have been synthesized. These include PNA monomers where glycine has been replaced by serine and threonine (O-glycosylated), derivs. of lysine and nor-alanine (C-glycosylated), and amide derivs. of aspartic acid (N-glycosylated). The Boc and Fmoc derivs. of these monomers were used for incorporation in PNA oligomers. Twelve PNA decamers containing the glycosylated units in one, two, or three positions were prepared, and the thermal stability (Tm) of their complexes with a complementary RNA was determined Incorporation of the glycosyl monomers reduced the duplex stability by 0-6° C per substitution. A cysteine was attached to the amino terminus of eight of the PNA decamers (Cys-CTCATACTCT-NH2) for easy conjugation to a [18F]radiolabeled N-(4-fluorobenzyl)-2-bromoacetamide. The in vivo biodistribution of these PNA oligomers was determined in rat 2 h after i.v. administration. Most of the radioactivity was recovered in the kidneys and in the urine. However, N-acetylgalactosamine (and to a lesser extent galactose and mannose)-modified PNAs were effectively targeting the liver (40-fold over unmodified PNA). Thus, the pharmacodistribution in rats of PNA oligomers can be profoundly changed by glycosylation. These results could be of great significance for PNA drug development, as they should allow modulation and fine-tuning of the pharmacokinetic profile of a drug lead.

IT 612491-01-7P 612491-03-9P 612491-04-0P
612491-06-2P 612491-22-2P 612491-23-3P
612491-25-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of glycosylated monomers for PNA synthesis and their effect on PNA/RNA hybridization or PNA biodistribution)

RN 612491-01-7 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-03-9 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-04-0 CAPLUS

CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-06-2 CAPLUS
CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-22-2 CAPLUS
CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-23-3 CAPLUS
CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612491-25-5 CAPLUS
CN L-Lysine, N2-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N2-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:451473 CAPLUS
DN 140:128552
TI Synthesis and applications of alkylated C-sugars as peptide bioconjugates
AU Brunel, Florence M.; Leduc, Anne-Marie; Mashuta, Mark S.; Taylor, K. Grant; Spatola, Arno F.
CS Department of Chemistry, University of Louisville, Louisville, KY, USA
SO Letters in Peptide Science (2003), Volume Date 2002, 9(2-3), 111-117
CODEN: LPSCEM; ISSN: 0929-5666
PB Kluwer Academic Publishers
DT Journal
LA English
OS CASREACT 140:128552
GI



AB Permethylated C-sugars affect the stability and solubility of their carbohydrate precursors and may represent an important group of bioconjugates. When properly functionalized, these units can be appended to the N- and C-termini or to the side chains of peptides or other therapeutic candidates. An amine-functionalized alkylated mannose derivative I (R = CH2NH2) was synthesized and its configuration was confirmed by determining the X-ray crystal structure of its nitrile precursor I (R = CN). An acid functionalized counterpart II, when attached to the N-terminus of a NR box peptide analog, improved binding to estrogen receptor β (ERβ) but not to ERα.

IT 457617-62-8P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and estrogen receptor binding activity of alkylated C-sugars as peptide bioconjugates)

RN 457617-62-8 CAPLUS
CN L-Glutamamide, N2-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-octonoyl)-L-lysyl-D-cysteinyl-L-isoleucyl-L-leucyl-L-cysteinyl-L-

arginyl-L-leucyl-L-leucyl-, cyclic (2→5)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:427283 CAPLUS
DN 139:230977
TI A serendipitous discovery of antifreeze protein-specific activity in C-linked antifreeze glycoprotein analogs

AU Eniade, Adewale; Purushotham, Madhusudhan; Ben, Robert N.; Wang, J. B.; Horwath, Kathleen
CS Department of Chemistry, State University of New York at Binghamton, Binghamton, NY, 13902, USA
SO Cell Biochemistry and Biophysics (2003), 38(2), 115-124
CODEN: CBBIFV; ISSN: 1085-9195
PB Humana Press Inc.
DT Journal
LA English
OS CASREACT 139:230977
AB Structurally diverse carbon-linked (C-linked) analogs of antifreeze glycoprotein (AFGP) have been prepared via linear or convergent solid phase synthesis. These analogs range in mol. weight from approx 1.5-4.1 KDa and do not possess the β-D-galactose-1,3-α-D-N-acetylgalactosamine carbohydrate moiety or the L-threonine-L-alanine-L-alanine polypeptide backbone native to the AFGP wild-type. Despite these dramatic structural modifications, the 2.7-KDa and 4.1-KDa analogs possess antifreeze protein-specific activity as determined by recrystn.-inhibition (RI) and thermal hysteresis (TH) assays. These analogs are weaker than the wild-type in their activity, but nanoliter osmometry indicates that these compds. are binding to ice and affecting a localized f.p. depression. This is the first example of a C-linked AFGP analog that possesses TH and RI activity and suggests that the rational design and synthesis of chemical and biol. stable AFGP analogs is a feasible and worthwhile endeavor. Given the low degree of TH activity, these compds. may prove useful for the protection of cells during freezing and thawing cycles.
IT 255851-86-6P 592532-40-6P 592532-44-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and evaluation of C-linked antifreeze glycoprotein oligopeptide analogs using recrystn. inhibition)
RN 255851-86-6 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 592532-40-6 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 592532-44-0 CAPLUS
CN Glycine, N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-C



PAGE 1-D



PAGE 2-A

PAGE 2-B



PAGE 2-C



PAGE 2-D

IT 255851-84-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and evaluation of C-linked antifreeze glycoprotein oligopeptide analogs using recrystn. inhibition)

RN 255851-84-4 CAPLUS

CN Glycine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:91084 CAPLUS
DN 139:261462
TI Synthesis of permethylated α-D-mannosyl-acetic acid, a new type of bio-conjugate
AU Brunel, Florence M.; Taylor, K. Grant; Spatola, Arno F.
CS Department of Chemistry and the Institute for Molecular Diversity and Drug Design, University of Louisville, Louisville, KY, 40292, USA
SO Tetrahedron Letters (2003), 44(6), 1287-1289
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:261462
GI



I

AB A concise stereoselective 3-step conversion of Me α-D-mannopyranoside to α-D-2,3,4,6-tetra-O-methyl-mannosyl-acetic acid I is described. After methylation of the alc. functions, an allylation is performed. Mannopyranoside The resulting alkene undergoes oxidative cleavage to the acid, an alkylated C-sugar, appropriate for attachment to peptides or other drug candidates for solubility enhancement. 8 Mg of leucine attached to I could be completely dissolved in 1 mL of ether, while leucine itself is insol. in ether. 6 Mg of leucine could not be dissolved in 0.25 mL of distilled water while 12 mg of leucine attached to the acid derivative was completely soluble in the same amount of water. With the bioconjugate attached, leucine water solubility was increased to at least 48 mg/mL; leucine itself is soluble only to 23 mg/mL.
IT 603131-28-8
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation,

nonpreparative)
(synthesis of permethylated mannosyl-acetic acid as a new type of bio-conjugate from mannopyranoside via stereoselective allylation and oxidative bond cleavage)
RN 603131-28-8 CAPLUS
CN L-Leucine, N-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:826257 CAPLUS
DN 138:170449
TI Synthesis of sugar azido or amino esters and their use as building blocks for the preparation of saccharide nucleosides
AU Xie, Juan
CS Universite Pierre et Marie Curie, Laboratoire de Chimie des Glucides, UMR 7613, Paris, 75005, Fr.
SO European Journal of Organic Chemistry (2002), (20), 3411-3418
CODEN: EJOCFK; ISSN: 1434-193X
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 138:170449
AB Several sugar azido or amino esters bearing an α- or a β-C-D-glucopyranosyl backbone have been prepared by TMSOTf/Ac2O-mediated α-C-glycosylation with concurrent selective removal of the primary benzyl group or selective acetolysis of the primary benzyl group of β-C-glycoside as key steps. Such structures have been successfully used as scaffolds for the synthesis of novel saccharide nucleosides.
IT 497227-05-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of sugar azido or amino esters and their use as building blocks for prepn. of saccharide nucleosides via C-glycosylation and regioselective acetolysis)
RN 497227-05-1 CAPLUS
CN Uridine, 5'-[[8-[[5-(acetylamino)-2,6-anhydro-5,7,8-trideoxy-1,3,4-tris-O-(phenylmethyl)-D-glycero-L-gulo-octitol-8-yl]amino]-2,6-anhydro-7,8-dideoxy-8-oxo-3,4,5-tris-O-(phenylmethyl)-L-glycero-L-gulo-octonoyl]amino]-5'-deoxy-2',3'-bis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B

Ph

Ph

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:716289 CAPLUS
DN 137:232918
TI Helicomimetics and stabilized LXXLL peptidomimetics
IN Spatola, Arno F.; Leduc, Anne-Marie
PA University of Louisville, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072597	A2	20020919	WO 2002-US7093	20020311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005054770 A1 20050310 US 2004-471120 20040923

PRAI US 2001-274846P P 20010309

WO 2002-US7093 W 20020311

OS MARPAT 137:232918

AB A helicomimetic compound for stabilizing the α-helical structure of a protein fragment, which can serve as an agonist or antagonist of protein-protein interactions, comprises a compound of structure R1-(Xn)-D-Cys-Y-Y-L-Cys-(Xn)-R2 [R1 is H, an alkyl, aryl, acetyl, formyl, or other blocking or solubilizing group, such as a polyethylene glycol (PEG) or other polyether moiety, linked to the N-terminal nitrogen through a carbon-nitrogen bond; X is one or more natural or unnatural amino acids, linked together in a chain from 0 to n in length; Y is a natural or unnatural amino acid, usually of the L-configuration, and with two such amino acids that need not be identical, separating the pairs of cysteines to form an i to i + 3 type of disulfide bridged unit; R2 is OH, NH2, NHR, OR, or other blocking or solubilizing group, such as polyethylene glycol (PEG) or other polyether moiety, linked to the C-terminal carbonyl through an oxygen or carbon or nitrogen linkage, such as an amide group]. The invention includes helix-stabilized compds. that contain the so-called NR Box found in a large number of Nuclear Receptor Coactivator Proteins. The NR Box sequence, consisting of Leu-Xxx-Yyy-Leu-Leu within a longer peptide, is found in both coactivator proteins and also in certain nuclear receptors. The Boc-based Merrifield solid-phase method was used to prepare linear and cyclic peptides, including H-Lys-His-Lys-Ile-Leu-His-Arg-Leu-Leu-Gln-Asp-Ser-Ser-OH (AML-I-89/2) and H-D-Lys-cyclo(D-Cys-Ile-Leu-Cys)-Arg-Leu-Leu-Gln-NH2 (AKG-I-28). Ki values are tabulated for the peptides against estrogen receptors (ER) alpha and beta. Short linear peptides that contain the LXXLL sequence, such as Leu-Asn-Gln-Leu-Leu, do not display any inhibitory activity with respect to the desired effect of inhibiting the binding of the estrogen receptors to the helical segment of coactivator proteins. Compds. that contain a D-Cys, L-Cys pairing are especially active with respect to binding inhibition.

IT 459844-33-8P, AML-I-31

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of α-helix stabilized LXXLL peptidomimetics)

RN 459844-33-8 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-manno-octonoyl)-L-leucyl-L-α-glutamyl-L-glutaminyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:716285 CAPLUS

DN 137:217246

TI Preparation of alkylated C-glycoside glycopeptides
IN Spatola, Arno F.; Taylor, K. Grant; Brunel, Florence
PA University of Louisville, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072593	A2	20020919	WO 2002-US7092	20020311
	WO 2002072593	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005059814	A1	20050317	US 2004-471328	20041026
PRAI	US 2001-274860P	P	20010309		
	WO 2002-US7092	W	20020311		

OS MARPAT 137:217246
GI



I

AB The present invention relates to alkylated C-glycoside glycopeptides which are new carbohydrate derivs. based on the "C-Sugar" platform. These alkylated C-sugars are converted from hydrophilic, hydrogen-bonded saccharide derivs. and are very stable, highly soluble and relatively low mol. weight structures. These alkylated C-sugars can serve as effective bio-conjugates and pharmaceutical carriers. The alkylated C-sugar have the formula I, wherein X = (CH2OR)n; n = 0-4; R = aryl, alkyl, or halogen-substituted aryl or alkyl, Y = (CH2)mNH2, (CH2)mCO2H, (CH2)mOH, (CH2)mCHO, (CH2)mCl, and m = 0-3.

IT 457617-62-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of alkylated C-glycoside glycopeptides)

RN 457617-62-8 CAPLUS

CN L-Glutamamide, N2-(3,7-anhydro-2-deoxy-4,5,6,8-tetra-O-methyl-D-glycero-D-talo-octonoyl)-L-lysyl-D-cysteinyl-L-isoleucyl-L-leucyl-L-cysteinyl-L-arginyl-L-leucyl-L-leucyl-, cyclic (2→5)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

L8 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:692298 CAPLUS
DN 138:385694
TI Expanding diversity: modification of linear and cyclic peptides by C-glycosylation and N-methylation
AU Brunel, Florence; Leduc, Anne-Marie; Singh, Sujan; Tang, Xiaoping; Vogel, David M.; Taylor, K. Grant; Spatola, Arno F.
CS Department of Chemistry and The Institute for Molecular Diversity and Drug Design, University of Louisville, Louisville, KY, 40292, USA
SO Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United

States, June 9-14, 2001 (2001), 170-171. Editor(s): Lebl, Michal; Houghten, Richard A. Publisher: American Peptide Society, San Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8

DT Conference

LA English

AB A symposium report. Several pseudoglycopeptides were synthesized through N-methylation and the introduction of C-glycosides.

IT 528598-56-3P 528598-60-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pseudoglycopeptides by C-glycosylation and N-methylation)

RN 528598-56-3 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-leucyl-L-α-glutamyl-L-glutaminyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528598-60-9 CAPLUS

CN L-Leucine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-leucyl-3-(2-naphthalenyl)alanyl-ψ(CH2-NH)-L-glutaminyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:623042 CAPLUS
DN 138:14142
TI Synthesis of a 56 component library of sugar β-peptides
AU Lohse, Anders; Schweizer, Frank; Hindsgaul, Ole
CS Department of Chemistry, University of Aarhus, Aarhus C., DK-8000, Den.
SO Combinatorial Chemistry and High Throughput Screening (2002), 5(5), 389-394
CODEN: CCHSFU; ISSN: 1386-2073
PB Bentham Science Publishers
DT Journal
LA English
OS CASREACT 138:14142
GI



I



II



III

AB Many biol. processes of vital importance are triggered by the mol. recognition of small carbohydrate units by proteins and receptors thus leading to the belief that carbohydrates could act as candidates for the design of new drugs. We have developed a new useful synthetic approach, which can be applied in a combinatorial manner, giving access to 1,1-di-substituted pyrans projecting amide side chains in both the α- and β-directions. Thus, treatment of the readily accessible hemiketal (I) with TFA followed by trimethylsilyl trifluoromethanesulfonate (TMSOTf) in the presence of a nitrile gives dihydrooxazinones (II) via a new type of modified intramol. Ritter reaction. The dihydrooxazinones can either be isolated or used directly in reactions with a broad variety of amines. Final deprotection furnishes the 1,1-di-substituted sugar β-peptides having the general structure (III).

IT 477718-63-1P 477718-64-2P 477718-65-3P
477718-66-4P 477718-67-5P 477718-68-6P
477718-70-0P 477718-71-1P 477718-72-2P
477718-73-3P 477718-77-7P 477718-78-8P

477718-79-9P 477718-80-2P 477718-81-3P
477718-82-4P 477718-84-6P 477718-85-7P
477718-86-8P 477718-87-9P 477718-91-5P
477718-92-6P 477718-93-7P 477718-94-8P
477718-95-9P 477718-96-0P 477718-98-2P
477718-99-3P 477719-00-9P 477719-01-0P
477801-13-1P 477801-14-2P 477801-15-3P
477801-16-4P 477801-17-5P 477801-18-6P
477801-20-0P 477801-21-1P 477801-22-2P
477801-23-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of sugar β-peptides combinatorial library using intramol. Ritter addition)

RN 477718-63-1 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-1-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-64-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclobutyl-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-65-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclopentyl-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-66-4 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cyclohexyl-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-67-5 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cycloheptyl-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-68-6 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-[[(1S,2R)-2-hydroxycyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-70-0 CAPLUS
CN Glycine, N-[3-(benzoylamino)-2,3-dideoxy-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-71-1 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-3-(benzoylamino)-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-72-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-73-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-77-7 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-1-piperidinyl-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-78-8 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-79-9 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-80-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-81-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-82-4 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[(1S,2R)-2-hydroxycyclohexyl]methyl]-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-84-6 CAPLUS
CN Glycine, N-[2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-85-7 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-86-8 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-87-9 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-octyl-3-[[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-91-5 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-1-piperidinyl-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-92-6 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-93-7 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-94-8 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-95-9 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-96-0 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[(1S,2R)-2-hydroxycyclohexyl]methyl]-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-98-2 CAPLUS
CN Glycine, N-[2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477718-99-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-2,3-dideoxy-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477719-00-9 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477719-01-0 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-octyl-3-[[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-13-1 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-N-1-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-14-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclobutyl-2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-15-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclopentyl-2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-16-4 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cyclohexyl-2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-17-5 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-18-6 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[[(1S,2R)-2-hydroxycyclohexyl]methyl]-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-20-0 CAPLUS
CN Glycine, N-[2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-21-1 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, N-(2-aminoethyl)-2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-22-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-N-[2-hydroxy-1-

(hydroxymethyl)ethyl]-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477801-23-3 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-[[(1,2,3,4,4a,9,10,10a-octahydro-9-phenanthrenyl)carbonyl]amino]-N-octyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:457030 CAPLUS
DN 137:263245
TI Preparation of glycosyl amino acids as building blocks for the combinatorial synthesis of neoglycoconjugates
AU Ziegler, Thomas; Roseling, Dirk; Subramanian, Lakshminarayanapuram R.
CS Institute of Organic Chemistry, University of Tubingen, Tubingen, D-72076, Germany
SO Tetrahedron: Asymmetry (2002), 13(9), 911-914
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:263245
AB Several neoglycosyl amino acids possessing a sugar residue, a spacer and a trifunctional amino acid moiety were synthesized both in solution and solid

phase by activating the carboxylic group as its pentafluorophenyl ester for condensation. The methodol. is useful for application in combinatorial syntheses of neoglycoconjugates as potential mimics for oligosaccharides.

IT 463313-68-0P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(prepn. of glycosyl amino acids as chiral synthons for the combinatorial synthesis of neoglycoconjugates and oligosaccharide mimics)

RN 463313-68-0 CAPLUS

CN L-Alanine, N-[5-(α-D-mannopyranosyloxy)pentyl]-L-α-asparaginyl-N-[5-(β-D-glucopyranosyloxy)pentyl]-L-α-asparaginyl-N-[5-(β-D-galactopyranosyloxy)pentyl]-L-α-asparaginyl-N6-(3,7-anhydro-2-deoxy-D-glycero-D-gulo-octonoyl)-D-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 463313-65-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of glycosyl amino acids as chiral synthons for the combinatorial synthesis of neoglycoconjugates and oligosaccharide mimics)
RN 463313-65-7 CAPLUS
CN L-Lysine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-gulo-octonoyl)-, pentafluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:182735 CAPLUS
DN 136:340919
TI β-C-Mannosides as Selectin Inhibitors
AU Kaila, Neelu; Chen, Lihren; Thomas, Bert E. , IV; Tsao, Desiree; Tam, Steve; Bedard, Patricia W.; Camphausen, Raymond T.; Alvarez, Juan C.; Ullas, Giliyar
CS Departments of Chemical Sciences, Biological Chemistry, and Immunology & Hemostasis, Wyeth Research, Cambridge, MA, 02140, USA
SO Journal of Medicinal Chemistry (2002), 45(8), 1563-1566
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:340919
AB Potential E- and P-selectin inhibitors were synthesized to explore a hydrophobic area on the E-selectin surface and the PSGL-1 protein binding site on the P-selectin surface that was recently defined by crystallog. Three series of mannose-based compds. (libraries A, B, and C) were synthesized using solution phase parallel synthesis. Biol. evaluation of these compds. was done using two ELISA-based assays and transferred NOE (trNOE) expts. Some of the compds. showed better activity than sLex in the P-selectin assay.
IT 418771-21-8P
RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial prepn. of β-C-mannosides as selectin

inhibitors)
RN 418771-21-8 CAPLUS
CN Pentanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-galacto-octonoyl)amino]-5-oxo-5-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 330955-04-9P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial prepn. of β-C-mannosides as selectin inhibitors)
RN 330955-04-9 CAPLUS
CN Benzenebutanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-galacto-octonoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 418771-13-8P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(combinatorial prepn. of β-C-mannosides as selectin inhibitors)
RN 418771-13-8 CAPLUS
CN L-Asparagine, N-(3,7-anhydro-2-deoxy-D-glycero-D-galacto-octonoyl)-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:51484 CAPLUS
DN 136:102620
TI Preparation of glycopyranoside phosphates for treatment of T lymphocyte mediated inflammatory diseases
IN Cowden, William Butler; Eschler, Bart Michael; March, Darren Ray; Francis, Douglas John; Gerba, Sendaba; Bartell, Gavin James; Charlton, Brett
PA Praxis Pharmaceuticals Pty. Ltd., Australia
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004472	A1	20020117	WO 2001-AU831	20010711
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2415214	A1	20020117	CA 2001-2415214	20010711
	EP 1301522	A1	20030416	EP 2001-949109	20010711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004501985	T	20040122	JP 2002-509335	20010711
	NZ 523565	A	20040326	NZ 2001-523565	20010711
	US 2003176363	A1	20030918	US 2003-338679	20030109
	US 6878690	B2	20050412		
PRAI	AU 2000-8723	A	20000711		
	WO 2001-AU831	W	20010711		

OS MARPAT 136:102620
GI



I

AB Glycopyranoside phosphates I, wherein R is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cyano, hydroxytetrahydropyranyloxyalkyl and (CH2)nCOX, wherein n represents an integer from 0 to 20 inclusive and X is independently selected from Y, OY' and NY"Y"' wherein Y is independently selected from H, alkyl, alkenyl, alkynyl aryl, heteroaryl, aralkyl, heteroaralkyl, carbohydrate and Y' is independently selected from H, alkyl, alkenyl, alkynyl aryl, heteroaryl aralkyl, heteroaralkyl, and carbohydrate Y" and Y"' are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl aralkyl, heteroaralkyl or acyl wherein each of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl and acyl may be optionally substituted, and the use thereof in treating diseases or conditions that are dependent on T-lymphocyte migration, as well as compns. containing said compds. Thus, phosphoric acid mono[6-(3-hexyloxypropyl)-3,4,5-trihydroxy-tetrahydropyran-2-yl-methyl] ester sodium salt was prepared Title glycosides may be used for treating diseases such as rheumatoid arthritis, multiple sclerosis, acute disseminated encephalomyelitis, psoriasis, Crohn's disease, T cell-mediated dermatitis, stromal keratitis, uveitis, thyroiditis, sialitis or type I diabetes.

IT 388593-58-6P 388593-75-7P 388593-81-5P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of glycopyranoside phosphates for treatment of T-lymphocyte mediated inflammatory diseases)

RN 388593-58-6 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 388593-75-7 CAPLUS

CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 Na

RN 388593-81-5 CAPLUS
CN D-manno-Octonamide, 3,7-anhydro-2-deoxy-N-(2-phenylethyl)-, 8-(dihydrogen phosphate), monosodium salt, (3ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 388593-61-1P 388593-62-2P 388593-63-3P
388593-64-4P 388593-78-0P 388593-79-1P
388593-80-4P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of glycopyranoside phosphates for treatment of T-lymphocyte mediated inflammatory diseases)
RN 388593-61-1 CAPLUS
CN L-Phenylalanine, N-[(3ξ)-4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-62-2 CAPLUS

CN L-Phenylalanine, N-[(3ξ)-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-63-3 CAPLUS
CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-8-O-(triphenylmethyl)-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-64-4 CAPLUS
CN L-Phenylalanine, N-[(3ξ)-4,5,6-tri-O-acetyl-3,7-anhydro-2-deoxy-D-manno-octonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-78-0 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-manno-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-79-1 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-phosphono-D-manno-octonoyl]-, 1,5-[bis(phenylmethyl)] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388593-80-4 CAPLUS
CN L-Glutamic acid, N-[(3ξ)-3,7-anhydro-2-deoxy-8-O-phosphono-D-manno-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:841083 CAPLUS
DN 136:134978
TI Chain Extension of Sugar δ-Lactones with the Enolate of tert-Butyl Bromoacetate and Elaboration into Functionalized C-Ketosides, C-Glycosides, and C-Glucosyl Glycines
AU Schweizer, Frank; Inazu, Toshiyuki
CS Noguchi Institute, Tokyo, 173-0003, Japan
SO Organic Letters (2001), 3(25), 4115-4118
CODEN: ORLEF7; ISSN: 1523-7060

PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:134978
GI



I



II

AB We describe the synthesis of a series of exocyclic sugar epoxides I prepared in a one-step procedure from sugar δ-lactones with the enolate of tert-Bu bromoacetate. Ring opening of the sugar oxiranes provides C-ketosides while reduction affords functionalized C-glycosides bearing an α-hydroxy ester moiety. The α-hydroxy ester can be converted into C-glucosyl glycine analogs II.

IT 391658-62-1P 391658-63-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chain extension of sugar δ-lactones with the enolate of tert-Bu bromoacetate and elaboration into functionalized C-ketosides, C-glycosides and C-glucosyl glycines)

RN 391658-62-1 CAPLUS
CN D-erythro-L-talo-Octonamide, 2-amino-3,7-anhydro-2-deoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 391658-63-2 CAPLUS
CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-(cyclohexylamino)-2-deoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:675317 CAPLUS
DN 136:53963
TI One pot conversion of ketoses into sugar β-peptides via a Ritter reaction
AU Schweizer, Frank; Lohse, Anders; Otter, Albin; Hindsgaul, Ole
CS Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Can.
SO Synlett (2001), (9), 1434-1436
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 136:53963
AB α-D-Galacto-2-deoxy-oct-3-ulopyranosonic acids can be converted into unnatural glycopeptides via a one pot intramol. Ritter reaction. Initially, the ketopyranoside reacts under Lewis acid catalyzed conditions with a nitrile (aromatic or aliphatic) to form a glycosylimino anhydride intermediate which can be isolated. Exposure of this intermediate to simple primary amines or amino acids produces novel sugar-β-peptides. Three different nitriles and three different amines have been used to generate 6 sugar β-peptides to demonstrate the generality of this reaction.
IT 381724-80-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sugar β-peptides via one-pot intramol. Ritter reaction)
RN 381724-80-7 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 381724-77-2P 381724-78-3P 381724-79-4P
381724-81-8P 381724-82-9P 381724-83-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of sugar β-peptides via one-pot intramol. Ritter reaction)

RN 381724-77-2 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-N-cycloheptyl-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-78-3 CAPLUS
CN Glycine, N-[3-(acetylamino)-2,3-dideoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-α-D-galacto-3-octulopyranosonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-79-4 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-(acetylamino)-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-81-8 CAPLUS

CN α-D-galacto-3-Octulopyranosonamide, N-cycloheptyl-2,3-dideoxy-3-[(phenylacetyl)amino]-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-82-9 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 2,3-dideoxy-3-[(phenylacetyl)amino]-N-(phenylmethyl)-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 381724-83-0 CAPLUS
CN α-D-galacto-3-Octulopyranosonamide, 3-(benzoylamino)-2,3-dideoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:601763 CAPLUS
DN 135:331663
TI A General Synthesis of Structurally Diverse Building Blocks for Preparing Analogues of C-Linked Antifreeze Glycoproteins
AU Eniade, Adewale; Murphy, Anastasia V.; Landreau, Geraldine; Ben, Robert N.
CS Department of Chemistry, State University of New York at Binghamton, Binghamton, NY, 13902, USA
SO Bioconjugate Chemistry (2001), 12(5), 817-823
CODEN: BCCHES; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
OS CASREACT 135:331663
AB A synthetic methodol. to afford unusual glycoconjugate building blocks useful for the solid-phase synthesis of C-linked antifreeze glycoprotein (AFGP) analogs is described. Such compds. are urgently required in order to elucidate the mol. mechanism by which AFGPs function. All reactions are general in nature and accommodate structural variation in the carbohydrate moiety, polypeptide backbone, and amino acid side chain.
IT 369649-14-9P 369649-16-1P 369649-17-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of glycopeptide building blocks that can be useful for the solid-phase synthesis of C-linked antifreeze glycoprotein analogs)
RN 369649-14-9 CAPLUS
CN L-Alanine, N6-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Bu-t



RN 369649-16-1 CAPLUS
CN Glycine, N6-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-L-prolyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 369649-17-2 CAPLUS
CN Glycine, N5-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-[(1,1-dimethylethyl)dimethylsilyl]-D-glycero-L-gluco-octonoyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-ornithylglycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:208811 CAPLUS
DN 134:353532
TI Fully Convergent Solid Phase Synthesis of Antifreeze Glycoprotein Analogues
AU Eniade, Adewale; Ben, Robert N.
CS Department of Chemistry, State University of New York, Binghamton, NY, 13902, USA
SO Biomacromolecules (2001), 2(2), 557-561
CODEN: BOMAF6; ISSN: 1525-7797
PB American Chemical Society
DT Journal
LA English
OS CASREACT 134:353532
AB The convergent solid phase synthesis of C-linked analogs of antifreeze glycoprotein (AFGP) has been achieved. In this approach, three to six carbohydrate residues are simultaneously coupled to a resin-bound polypeptide. Glycopeptides ranging from 1.6 to 3.0 kDa are easily prepared in 26-44% yield demonstrating the utility of this approach.
IT 339149-38-1P 339149-39-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of antifreeze glycoprotein analogs using convergent solid phase synthesis techniques)
RN 339149-38-1 CAPLUS
CN Glycine, N-acetylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 339149-39-2 CAPLUS
CN Glycine, N-acetylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycylglycyl-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B









PAGE 2-A



PAGE 2-C



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:125930 CAPLUS
DN 132:322131
TI Glycomimetics: A Programmed Approach toward Neoglycopeptide Libraries
AU Arya, Prabhat; Kutterer, Kristina M. K.; Barkley, Angela
CS Chemical Biology Program, Steacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON, K1A 0R6, Can.
SO Journal of Combinatorial Chemistry (2000), 2(2), 120-126
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
AB A programmed synthesis of neoglycopeptides has been developed in which two, similar or different, glycoside moieties could be attached either (i) at the N-terminal of short peptides or (ii) one at the N-internal and the other(s) at the N-terminal site, in a highly flexible and controlled manner. A stepwise branching of N-terminal peptides has been achieved by glycoside aldehyde reductive amination followed by the glycoside carboxylic acid coupling. In another approach, after N-alkylation with glycoside aldehyde, the N-glycosylated derivative is subjected to peptide synthesis. This is then followed by the attachment of the second glycoside moiety at the N-terminal using either glycoside aldehyde or glycoside carboxylic acid derivative Alternatively, the attachment of second and third glycoside derivs. could be achieved simultaneously, by reductive amination/carboxylic acid couplings. The methodologies presented here are highly versatile and combine diversity in both peptides/pseudopeptides and glycoside moieties.
IT 193156-93-3P 267234-65-1P 267234-66-2P
267234-67-3P 267234-68-4P 267234-69-5P
267234-70-8P 267234-71-9P 267234-72-0P
267234-73-1P 267234-74-2P 267234-75-3P

267234-76-4P 267234-77-5P 267234-78-6P
267234-79-7P 267234-80-0P 267234-81-1P
267234-82-2P 267234-83-3P 267234-84-4P
267234-85-5P 267234-86-6P 267234-87-7P
267234-88-8P 267234-89-9P 267234-90-2P
267234-91-3P 267234-92-4P 267234-93-5P
267234-94-6P 267234-95-7P 267234-96-8P
267234-97-9P 267234-98-0P 267234-99-1P
267235-00-7P 267235-01-8P 267235-02-9P
267235-09-6P 267235-10-9P 267235-11-0P
267235-12-1P 267235-13-2P 267235-14-3P
267235-15-4P 267235-16-5P 267235-17-6P
267235-18-7P 267235-19-8P 267235-20-1P
267235-21-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of neoglycopeptide libraries for use as glycomimetics)

RN 193156-93-3 CAPLUS
CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-65-1 CAPLUS
CN D-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl)(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-66-2 CAPLUS
CN L-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl)(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-67-3 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[(2-amino-2-oxoethyl)(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-68-4 CAPLUS
CN D-glycero-L-galacto-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-69-5 CAPLUS
CN L-glycero-L-galacto-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-

anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-70-8 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-71-9 CAPLUS
CN D-glycero-L-galacto-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-72-0 CAPLUS
CN L-glycero-L-galacto-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-73-1 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-74-2 CAPLUS
CN L-glycero-L-galacto-Octitol, 8-[(2-amino-2-oxoethyl)(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-manno-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-75-3 CAPLUS
CN L-Alanine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-76-4 CAPLUS
CN L-Phenylalanine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-77-5 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-78-6 CAPLUS
CN D-glycero-D-gulo-Octitol, 1-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-79-7 CAPLUS
CN D-glycero-D-manno-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-80-0 CAPLUS
CN D-glycero-D-manno-Octitol, 8-[[(1S)-2-amino-1-methyl-2-oxoethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-81-1 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-82-2 CAPLUS
CN D-glycero-D-gulo-Octitol, 1-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-83-3 CAPLUS

CN D-glycero-D-manno-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-84-4 CAPLUS
CN D-glycero-D-manno-Octitol, 8-[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-85-5 CAPLUS
CN D-glycero-L-gulo-Octitol, 8-[[(1S)-1-(aminocarbonyl)-3-methylbutyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-86-6 CAPLUS
CN D-glycero-D-gulo-Octitol, 1-[[(1S)-1-(aminocarbonyl)-3-methylbutyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-3,7-anhydro-1,2-dideoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-87-7 CAPLUS
CN D-glycero-D-manno-Octitol, 8-[[(1S)-1-(aminocarbonyl)-3-methylbutyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-88-8 CAPLUS
CN D-glycero-D-manno-Octitol, 8-[[(1S)-1-(aminocarbonyl)-3-methylbutyl](4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-

octonoyl)amino]-2,6-anhydro-7,8-dideoxy-, 1,3,4,5-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-89-9 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-90-2 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-91-3 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-92-4 CAPLUS
CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-93-5 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-94-6 CAPLUS
CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-95-7 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-96-8 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-97-9 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-98-0 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267234-99-1 CAPLUS
CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-00-7 CAPLUS
CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-01-8 CAPLUS
CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-02-9 CAPLUS
CN L-Leucinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-09-6 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-10-9 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-11-0 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-12-1 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-13-2 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-14-3 CAPLUS
CN L-Alaninamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-phenylalanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-15-4 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-

octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-16-5 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-17-6 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-D-ido-octonoyl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-18-7 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-19-8 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-20-1 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267235-21-2 CAPLUS
CN Glycinamide, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)-L-alanyl-N2-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:390408 CAPLUS
DN 131:45047
TI Preparation of sialyl Lewisx and sialyl Lewisa glyco-mimetics as selectin inhibitors
IN Anderson, Mark B.; Kobayashi, Yoshiyuki; Itoh, Kazuhiro; Holme, Kevin R.; Cui, Jingrong; Fugedi, Peter; Peto, Csaba F.; Wang, Li; Vazir, Harish
PA Glycomed Incorporated, USA; Sankyo Co., Ltd.
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929705	A2	19990617	WO 1998-US25783	19981204
	WO 9929705	A3	19990819		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9918042	A	19990628	AU 1999-18042	19981204
PRAI	US 1997-67971P	P	19971208		
	WO 1998-US25783	W	19981204		

OS MARPAT 131:45047
GI



I



II



III



IV

AB The present invention provides a series of compds. in the form of chemical and physiol. stable glyco-mimics or glyco-epitopes I-III and MO2C(CH2)nNHC(O)YG wherein W is a covalent bond, -C(=O)-, -C(=O)-CH2-, -C(=O)-CH2-CH2-, -C(=O)-CH=CH-, -C(=O)-CH(-NHAc)-CH2-, -C(=O)-CH2-CHOH-, -C(=O)-CH(-NH-C(=O)-O-t-Bu)-CH2-, -C(=S)-, -C(=S)-S-, -C(=S)-S-CH2-, -C(=S)-CH2-CH2-, -C(=S)-NH-, -CH2-CH2-O-, -CH2-CH(CH3)-CH2-, -CH2-CH(CH2OH)-CH2-, -CH2-C(=CH2)-CH2-; X is -NR3-, -C(R8)2-, -NR8-, CH-S-sialic acid, CH-O-sialic acid, -O- or -S-; Y is a covalent bond, -(CH2)n-, -CH2-NH-C(=O)-, or -NH-C(=O)-; R1-R9 are independently selected from the group consisting of -H, -OH, alkyl, -CO2M, -CH2-CO2M, -CO2Me, -CH2-CO2Me, -CO2Et, -CH2CO2Et, -CH2-CH=CH-CO2M, -CH2-CH=CH-CO2Me, -CH2-CH=CH-CO2Et, -OSO3M, -CH2-OSO3M, -OPO3M2, -CH2-OPO3M2 with the proviso that at least one of R1-R9 is not -H or -OH; G is heterocycle; M is a metal, n is 1-3, that serve to functionally mimic the active features of biol. important oligosaccharides, such as but not limited to sialyl Lewisx and sialyl Lewisa. These structural glyco-mimetics are useful in the treatment of acute and chronic diseases and asthma. These compds. also are useful in the treatment of other selectin-mediated disorders, such as inflammation, cancer, diabetes, obesity, lung vasculitis, cardiac injury, reperfusion injuries, thrombosis, tissue rejection, arthritis, inflammatory bowel disease and pulmonary inflammation. Thus, carboxymethyl-piperidine-N-isopropenyl-C-fucoside IV was prepared and tested as selectin inhibitor (IC50 > 2500 μM).

IT 227460-65-3P 227460-71-1P 227460-73-3P
227460-80-2P 227460-82-4P 227460-86-8P
227460-87-9P 227461-37-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sialyl Lewisx and sialyl Lewisa glyco-mimetics as selectin inhibitors)

RN 227460-65-3 CAPLUS

CN Butanoic acid, 4-[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-71-1 CAPLUS
CN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-73-3 CAPLUS
CN Butanoic acid, 4-[[[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-80-2 CAPLUS
CN β-Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-82-4 CAPLUS
CN β-Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-86-8 CAPLUS
CN β-Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227460-87-9 CAPLUS
CN β-Alanine, N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 227461-37-2 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:67133 CAPLUS
DN 130:182670
TI An access to glycoconjugate libraries through multicomponent reactions
AU Lockhoff, Oswald
CS Bayer AG, Central Research, ZF-WF Q18, Leverkusen, D-51368, Germany
SO Angewandte Chemie, International Edition (1999), Volume Date 1998, 37(24), 3436-3439
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
AB A multicomponent condensation (MCC)-based combinatorial synthesis of glycoconjugate libraries using appropriate carbohydrate derivs. having aldehyde, amino, carboxylic acid and isocyanide groups with solid-phase Ugi reactions is discussed.
IT 204069-02-3P 204069-07-8P 204069-19-2P
204069-21-6P 204069-23-8P 204069-25-0P
204069-33-0P 220689-70-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(multicomponent condensation combinatorial synthesis of glycoconjugate libraries through Ugi reactions)
RN 204069-02-3 CAPLUS
CN D-erythro-L-galacto-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-07-8 CAPLUS
CN D-erythro-L-talo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-

anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-19-2 CAPLUS
CN D-erythro-L-talo-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-21-6 CAPLUS
CN D-erythro-L-galacto-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-23-8 CAPLUS
CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-25-0 CAPLUS
CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-33-0 CAPLUS
CN D-glycero-D-gulo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220689-70-3 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:756365 CAPLUS
DN 130:95830
TI Automated, Solid-Phase Synthesis of C-Neoglycopeptides: Coupling of Glycosyl Derivatives to Resin-Bound Peptides
AU Kutterer, Kristina M. K.; Barnes, Michael L.; Arya, Prabhat
CS Steacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON, K1A 0R6, Can.
SO Journal of Combinatorial Chemistry (1999), 1(1), 28-31
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
GI



I II

AB A fully automated solid-phase synthesis of C-neoglycopeptides has been developed using a convergent strategy. In this approach, C-glycoside derivs. I and II were coupled to resin-bound peptides using a peptide synthesizer. An advantage of the convergent approach is the ability to introduce multiple glycoside units late in the synthesis. The approach presented is highly versatile and efficient and could be used for building C-neoglycopeptide libraries. In this study, neoglycopeptides Fmoc-Lys(R)-Gly2-NH2 (R = acyl group from I, n = 1; R = acyl group from II, n = 3) were obtained from the coupling of C-glycoside derivs. I and II to the free side chain amino group of short lysine-containing peptides. A similar approach was developed for the synthesis of bivalent neoglycopeptides Fmoc-Lys(R)-Gly-Ala-Gly-Lys(R)-Glyn-NH2 in an automated manner. The successful syntheses of these C-neoglycopeptides are the first examples of coupling of C-glycosyl carboxyl derivs. to the side chain amino groups of resin-bound peptides.

IT 193156-93-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(automated, solid-phase synthesis of C-neoglycopeptides via coupling of glycosyl derivs. to resin-bound peptide side chains)

RN 193156-93-3 CAPLUS

CN Glycine, N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219543-11-0P 219543-12-1P 219543-13-2P
219543-14-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(automated, solid-phase synthesis of C-neoglycopeptides via coupling of glycosyl derivs. to resin-bound peptide side chains)

RN 219543-11-0 CAPLUS

CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219543-12-1 CAPLUS
CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219543-13-2 CAPLUS
CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysylglycyl-L-alanylglycyl-N6-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 219543-14-3 CAPLUS

CN Glycinamide, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycyl-L-alanylglycyl-N6-[N-(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(1,3,4,5-tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A





PAGE 2-B



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:630402 CAPLUS
DN 129:331035
TI Synthesis of sialyl Lewis X mimetics using the Ugi four-component reaction
AU Tsai, Chung-Ying; Park, William K. C.; Weitz-Schmidt, Gabriele; Ernst, Beat; Wong, Chi-Huey
CS Department Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(17), 2333-2338
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB Application of the Ugi four-component condensation to rapidly synthesize a library of glycopeptide mimics, e.g. I [R = Me, CF3, (CH2)4Me, (CH2)12Me, CH:CHCH:CHMe, Ph, 1-naphthylmethyl, 2-naphthylmethyl, 4-PhC6H4,

1-fluorenyl, 9-fluorenylmethyl] of the tetrasaccharide SLex as inhibitors of E- and P-selectin, and to study the effect of varied functionality in mimics on the inhibition is described.

IT 215163-38-5P 215163-39-6P 215163-40-9P
215163-41-0P 215163-42-1P 215163-43-2P
215163-44-3P 215163-45-4P 215163-46-5P
215163-47-6P 215163-48-7P 215163-49-8P
215163-51-2P 215163-66-9P 215163-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(use of Ugi four-component reaction in prepn. of sialyl Lewis X glycopeptide mimics as selectin inhibitors)

RN 215163-38-5 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-39-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-40-9 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 215163-41-0 CAPLUS
CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 215163-42-1 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 215163-43-2 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

RN 215163-44-3 CAPLUS
CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-45-4 CAPLUS
CN Glycine, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-D-alanyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-46-5 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-47-6 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1R)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-48-7 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1S)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 215163-49-8 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-8-O-phenyl-D-glycero-D-talo-octonoyl)-N-[(1R)-2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-51-2 CAPLUS
CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-66-9 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 215163-67-0 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 215163-31-8P 215163-32-9P 215163-33-0P
215163-34-1P 215163-35-2P 215163-36-3P
215163-37-4P 215163-64-7P 215163-65-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(use of Ugi four-component reaction in prepn. of sialyl Lewis X glycopeptide mimics as selectin inhibitors)

RN 215163-31-8 CAPLUS

CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-32-9 CAPLUS

CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 215163-33-0 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 215163-34-1 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-8-O-methyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-35-2 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-phenyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-36-3 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-phenyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[2-[(1,1-dimethylethyl)amino]-1-methyl-2-oxoethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-37-4 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-N-[(1S)-4-oxo-4-(phenylmethoxy)-1-[(phenylmethoxy)carbonyl]butyl]-L-α-glutamyl-, 2-methyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215163-64-7 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6-tris-O-(phenylmethyl)-8-O-5,8,11,14-tetraoxahexadec-1-yl-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 215163-65-8 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-[3-[4-(4-phenoxyphenoxy)phenyl]propyl]-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-

octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 215163-50-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(use of Ugi four-component reaction in prepn. of sialyl Lewis X glycopeptide mimics as selectin inhibitors)

RN 215163-50-1 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)-N-[(1S)-1,3-dicarboxypropyl]-L-α-glutamyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:348137 CAPLUS
DN 129:81942
TI Diversity of C-linked neoglycopeptides for the exploration of subsite-assisted carbohydrate binding interactions
AU Arya, Prabhat; Kutterer, Kristina M. K.; Qin, Huiping; Roby, Johanne; Barnes, Michael L.; Kim, Jin M.; Roy, Rene
CS Steacie Institute for Molecular Sciences, National Research Council of Canada, Ottawa, ON, K1A 0R6, Can.
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(10), 1127-1132
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB Diversity of α-galactose based C-linked neoglycopeptides has been developed to explore the importance of subsite-assisted carbohydrate binding interactions. Deprotected C-linked neoglycopeptides, e.g., Ac-Lys(COCH2R)-Gly-NH2 (R = 1-deoxy-C1-α-D-galacto-pyranosyl) (1b) and (S)-AcNHCH[(CH2)4N[(CH2)2R]2]CO-Gly-NH2 (same R) (2b), were synthesized and tested in competitive inhibition assays using a model enzyme-linked lectin (e.g., Maclura pomifera). Compound 2b, with two α-galactoside units on the side chain of the lysine residue of the dipeptide backbone, exhibited a remarkable effect with a 2.82-fold increase in its inhibitory properties (IC50 1.48 mM) in comparison to 1b (IC50 4.18 mM).
IT 209265-32-7P 209265-34-9P 209265-35-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(diversity of C-linked neoglycopeptides for exploration of subsite-assisted carbohydrate binding interactions)
RN 209265-32-7 CAPLUS
CN Glycinamide, N2-acetyl-N6-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209265-34-9 CAPLUS
CN Glycinamide, N2-acetyl-N6-[N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-N-(2,6-anhydro-7,8-dideoxy-D-glycero-L-galacto-octitol-8-yl)glycyl]-L-lysyl-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209265-35-0 CAPLUS
CN Glycinamide, N2-acetyl-N6-[N3,N5-bis[N-(3,7-anhydro-2-deoxy-D-glycero-L-gluco-octonoyl)-L-alanylglycyl]-3,5-diaminobenzoyl]-L-lysyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:293511 CAPLUS
DN 129:4814
TI Preparation of sialyl Lewis X mimetics as E-selectrin inhibitors
IN Wong, Chi-huey; Moris-Varas, Francisco; Lin, Chun-cheng; Marron, Thomas G.; Woltering, Thomas; Weitz-Shmidt, Gabriele; Jablonowski, Jill
PA Novartis A.-G., Switz.; Scripps Research Institute

SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818805	A2	19980507	WO 1997-EP5909	19971027
	WO 9818805	A3	20030417		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5830871	A	19981103	US 1996-744744	19961028
	US 5837862	A	19981117	US 1996-764315	19961212
	AU 9853137	A	19980522	AU 1998-53137	19971027
PRAI	US 1996-744744	A	19961028		
	US 1996-764315	A	19961212		
	US 1997-896452	A	19970718		
	WO 1997-EP5909	W	19971027		

OS MARPAT 129:4814
GI



I



II

AB Sialyl Lewis X mimetics which mimic the inhibition of selectin-mediated cellular adhesion by sialyl Lewis X having a core of formula [(I); R = Me, OH, carboxylate-containing sugar residue; Y = alkene; R1 = OH, NH2, amide, amino acid] were prepared Thus, compds. such as II were prepared and tested for ability to block the adhesion of HL-60 cells to immobilized sol-E-selectin. Compds. of formula I showed inhibition at 3mM of 70-80%, or IC50 values from 0.1-0.2mM.

IT 186532-53-6P 186532-55-8P 186532-57-0P
194980-12-6P 194980-14-8P 204458-84-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sialyl Lewis X mimetics as E-selectrin inhibitors)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-55-8 CAPLUS
CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-57-0 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-12-6 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-14-8 CAPLUS
CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-84-4 CAPLUS
CN β-D-Talopyranoside, methyl 2-[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 194980-10-4 194980-11-5 204458-91-3
204458-92-4 207387-06-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of sialyl Lewis X mimetics as E-selectrin inhibitors)
RN 194980-10-4 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-11-5 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-91-3 CAPLUS
CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-92-4 CAPLUS
CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207387-06-2 CAPLUS
CN β-D-Galactopyranoside, methyl 2-[[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]amino]-3-O-(carboxymethyl)-2-deoxy-4,6-O-[(S)-phenylmethylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:257568 CAPLUS
DN 128:321842
TI Synthesis of benzylated (R)- and (S)-aminoethyl-C-α-D-mannosides as conformationally restricted building blocks for the preparation of E- and P-selectin antagonists
AU Roche, Didier; Banteli, Rolf; Winkler, Tammo; Casset, Florence; Ernst, Beat
CS Novartis Pharma Corp., East Hanover, NJ, 07936, USA
SO Tetrahedron Letters (1998), 39(17), 2545-2548
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB A straightforward synthesis for (R)- and (S)-aminoethyl-C-α-D-mannosides has been developed. The conformationally restricted mannosides serve as building blocks for the synthesis of a new class of selectin antagonists of type A.
IT 207107-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzylated (R)- and (S)-aminoethyl-C-mannosides as conformationally restricted building blocks for the prepn. of E- and P-selectin antagonists)
RN 207107-97-9 CAPLUS
CN D-erythro-L-allo-Octonamide, 3,7-anhydro-2-deoxy-2-methyl-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:184112 CAPLUS
DN 128:230687
TI Preparation of glycoconjugate amino acids for use as a combinatorial library for receptor-site screening
IN Lockhoff, Oswald
PA Bayer A.-G., Germany
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19636538	A1	19980312	DE 1996-19636538	19960909
EP 832898	A2	19980401	EP 1997-114805	19970827
EP 832898	A3	19980429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CA 2214728	A1	19980309	CA 1997-2214728	19970905
JP 10101634	A	19980421	JP 1997-259273	19970908
PRAI DE 1996-19636538	A	19960909		

OS CASREACT 128:230687; MARPAT 128:230687
GI



II

AB Using four-component reactions, title compds. R2CONR1CHRCOXR3 [(I); R = R1 = (same or different) alkyl, cycloalkyl, aralkyl, aromatic heterocycle, (substituted) tetrahydro-furanyl, (substituted) tetrahydro-pyranyl; R2 = H, R1; R3 = H, R1; X = O, NH, N(alkyl), S] were prepared as possible screening reagents for cellular receptor sites (no data), from reaction mixts. of an aldehyde, an amine, a carbon-acid, and an isonitrile, any of which could be a carbohydrate. Thus, 2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-D-gulo-heptose, MeO-C6H4-4-CH2NH2, CH3CO2H, and c-C6H11NC were reacted to give II (65% over all yield, as a mixture of diastereomers).

IT 204069-02-3P 204069-07-8P 204069-19-2P
204069-21-6P 204069-23-8P 204069-25-0P
204069-33-0P 204069-35-2P 204069-37-4P
204069-39-6P 204069-40-9P 204069-44-3P
204069-48-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of glycoconjugate amino acids for use as a combinatorial library for receptor site screening)

RN 204069-02-3 CAPLUS
CN D-erythro-L-galacto-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-07-8 CAPLUS
CN D-erythro-L-talo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-19-2 CAPLUS
CN D-erythro-L-talo-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-21-6 CAPLUS
CN D-erythro-L-galacto-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-23-8 CAPLUS
CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-25-0 CAPLUS
CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-33-0 CAPLUS
CN D-glycero-D-gulo-Octonamide, 2-[acetyl[(4-methoxyphenyl)methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-35-2 CAPLUS
CN D-erythro-L-talo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 204069-37-4 CAPLUS

CN D-erythro-L-galacto-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-cyclohexyl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 204069-39-6 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][(4-methoxyphenyl)methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-40-9 CAPLUS
CN D-glycero-D-gulo-Octonamide, 2-[acetyl[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204069-44-3 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 204069-48-7 CAPLUS
CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-N-[[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-galactopyranosyl]methyl]-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 204069-46-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of glycoconjugate amino acids for use as a combinatorial library for receptor site screening)

RN 204069-46-5 CAPLUS

CN D-glycero-D-gulo-Octonamide, 3,7-anhydro-2-[[2,6-anhydro-3,4,5,7-tetrakis-O-(phenylmethyl)-D-glycero-D-gulo-heptonoyl][[2,3,4,6-tetrakis-O-(phenylmethyl)-β-D-glucopyranosyl]methyl]amino]-N-1-cyclohexen-1-yl-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-, (2ξ)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L8 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:163599 CAPLUS
DN 128:230633
TI Preparation of sialyl Lewis x mimetics as E-selectin inhibitors
IN Wong, Chi-Huey; Lin, Chun-Cheng; Woltering, Thomas J.; Marron, Thomas G.; Moris-Varas, Francisco; Jablonowski, Jill; Weitz-Schmidt, Gabriele
PA Novartis A.-G., Switz.; Scripps Research Institute; Wong, Chi-Huey; Lin, Chun-Cheng; Woltering, Thomas J.; Marron, Thomas G.; Moris-Varas, Francisco; Jablonowski, Jill; Weitz-Schmidt, Gabriele
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808854	A2	19980305	WO 1997-EP4649	19970826
	WO 9808854	A3	19980820		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5830871	A	19981103	US 1996-744744	19961028

	US 5837862	A	19981117	US 1996-764315	19961212
	AU 9747004	A	19980319	AU 1997-47004	19970826
PRAI	US 1996-24556P	P	19960826		
	US 1996-744744	A	19961028		
	US 1996-764315	A	19961212		
	WO 1997-EP4649	W	19970826		

OS MARPAT 128:230633

GI



I



II

AB Sialyl Lewis X mimetics which mimic the inhibition of selectin-mediated cellular adhesion by sialyl Lewis X having a core of formula I (R1 = Me, OH, carboxylate-containing sugar residue; Y = alkylene; R2 = hydroxy, amine, amide, amino acid) were prepared Thus, II was prepared and tested for ability to block the adhesion of HL-60 cells to immobilized sol-E-selectin (IC50 = 0.1-0.2 mM).

IT 186532-53-6P 186532-55-8P 186532-57-0P
194980-12-6P 204458-84-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of sialyl Lewis x mimetics as E-selectin inhibitors)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-55-8 CAPLUS

CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-57-0 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-12-6 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-84-4 CAPLUS
CN β-D-Talopyranoside, methyl 2-[(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)amino]-3-O-(carboxymethyl)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 194980-11-5 194980-14-8 204458-91-3
204458-92-4 204458-93-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of sialyl Lewis x mimetics as E-selectin inhibitors)

RN 194980-11-5 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-14-8 CAPLUS

CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-91-3 CAPLUS

CN Glycine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-92-4 CAPLUS

CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204458-93-5 CAPLUS
CN L-Tyrosine, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-O-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:667131 CAPLUS
DN 127:229196
TI Small Molecules as Structural and Functional Mimics of Sialyl Lewis X in Selectin Inhibition: A Remarkable Enhancement of Inhibition by Additional Negative Charge and/or Hydrophobic Group
AU Wong, Chi-Huey; Moris-Varas, Francisco; Hung, Shang-Cheng; Marron, Thomas G.; Lin, Chun-Cheng; Gong, Ke Wei; Weitz-Schmidt, Gabriele
CS Department of Chemistry, Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of the American Chemical Society (1997), 119(35), 8152-8158
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 127:229196
AB Several sialyl Lewis X (SLex) mimics that contain the essential functional groups for receptor interaction and a neg. charge or a hydrophobic group have been developed as inhibitors of E-, P-, and L-selectins. Some of the mimics exhibit selectin inhibition activities 103-104-fold more potent than does the natural ligand tetrasaccharide, with IC50 in the low micromolar to high nanomolar range. The syntheses of these mimics are relatively simple, using TMSOTf-Ac2O mediated C-glycosylation with concurrent selective deprotection of the primary benzyl group and enzymic aldol addition reactions as key steps.
IT 194980-10-4P 194980-11-5P 194980-13-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; small mols. as structural and functional mimics of sialyl Lewis x in selectin inhibition in relation to addnl. neg. charge and/or hydrophobic Group)

RN 194980-10-4 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-11-5 CAPLUS

CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-13-7 CAPLUS

CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-4,5,6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 865714-47-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(mimics; small mols. as structural and functional mimics of sialyl Lewis x in selectin inhibition in relation to addnl. neg. charge and/or hydrophobic Group)
RN 865714-47-2 CAPLUS
CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-8-O-hexadecyl-4,5;6-tris-O-(phenylmethyl)-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 186532-57-0P 194980-12-6P 194980-14-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(small mols. as structural and functional mimics of sialyl Lewis x in selectin inhibition in relation to addnl. neg. charge and/or hydrophobic Group)
RN 186532-57-0 CAPLUS
CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-12-6 CAPLUS
CN L-Glutamic acid, N-[3,7-anhydro-2-deoxy-8-O-hexadecyl-D-glycero-D-talo-octonoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194980-14-8 CAPLUS
CN Benzoic acid, 3-[[3,7-anhydro-2-deoxy-6-O-hexadecyl-D-glycero-D-talo-octonoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:528274 CAPLUS
DN 127:109119
TI Stereoselective Synthesis of C-Amino-Substituted D-Mannopyranosides. Easy Preparation of Novel Inhibitors for Mannosidases
AU Lopez-Herrera, Fidel J.; Sarabia-Garcia, Francisco; Heras-Lopez, A.; Pino-Gonzalez, M. S.
CS Departamento de Bioquimica Biologia Molecular y Quimica Organica Facultad de Ciencias, Universidad de Malaga, Malaga, 29071, Spain
SO Journal of Organic Chemistry (1997), 62(17), 6056-6059
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
GI



I

AB Title mannopyranosides, e.g. I, were prepared via condensation of 2,3:4,6-di-O-isopropylidene-D-mannopyranose with sulfur ylide Me2SCHCONEt2. I showed inhibitory activity against β-mannosidase (no data).
IT 191282-00-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereoselective prepn. of C-amino-substituted mannopyranosides as mannosidase inhibitors)

RN 191282-00-5 CAPLUS

CN D-erythro-L-manno-Octonamide, 3,7-anhydro-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 191282-01-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective prepn. of C-amino-substituted mannopyranosides as mannosidase inhibitors)

RN 191282-01-6 CAPLUS

CN D-erythro-L-gluco-Octonamide, 2-amino-3,7-anhydro-2-deoxy-N,N-diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:10067 CAPLUS

DN 126:144480

TI C-Mannose derivatives as potent mimics of sialyl Lewis X

AU Marron, Thomas G.; Woltering, Thomas J.; Weitz-Schmidt, Gabriele; Wong, Chi-Huey

CS Dep. Chem., Scripps Res. Inst., La Jolla, CA, 92037, USA

SO Tetrahedron Letters (1996), 37(50), 9037-9040
CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier

DT Journal

LA English

GI



I

AB The prepn. of five sialyl Lewis X mimetics, e.g. I, was described. Mimic I showed activities five-fold better than sialyl Lewis X as selectin inhibitors.

IT 186532-53-6P 186532-55-8P 186532-57-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of C-mannoses as selectin inhibitors and potent mimics of sialyl Lewis X)

RN 186532-53-6 CAPLUS

CN Glycine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-55-8 CAPLUS

CN L-Tyrosine, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186532-57-0 CAPLUS

CN L-Glutamic acid, N-(3,7-anhydro-2-deoxy-D-glycero-D-talo-octonoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:650028 CAPLUS
DN 126:19208
TI Generation of C-Glycoside Peptide Ligands for Cell Surface Carbohydrate Receptors Using a Four-Component Condensation on Solid Support
AU Sutherlin, Daniel P.; Stark, Todd M.; Hughes, Robert; Armstrong, Robert W.
CS Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90095, USA
SO Journal of Organic Chemistry (1996), 61(23), 8350-8354
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
AB The first synthesis of a C-glycopeptide combinatorial library on solid support is described. The compds. are generated on the Rink resin through an Ugi reaction, a multiple component condensation (MCC) that combines an aldehyde, carboxylic acid, isocyanide and resin-bound amine to yield an α-acylamino amide. Utilizing C-glycosides as the aldehyde and/or carboxylic acid input, compds. with a highly dense core of functionality can be rapidly synthesized. These compds. can be used to study the binding requirements of the cell surface carbohydrate receptors. This method is demonstrated in the synthesis of eight diverse structures, highlighting the general nature of this approach, and more specifically in the synthesis of a 96 compound combinatorial library of C-glycopeptides directed towards the receptors of the sialyl Lewis X blood group determinant. Two protecting group strategies for the sugar hydroxyls have been implemented, one employing benzyl ethers that can be cleanly removed after the compds. cleavage from the resin, and the other using acetoxy groups that can be removed prior to cleavage. Both strategies yield compds. of purity sufficient for high throughput screening.
IT 184100-14-9P 184100-34-3P 184100-35-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(generation of C-glycoside peptide ligands for cell surface carbohydrate receptors using four-component condensation on solid support)
RN 184100-14-9 CAPLUS
CN Glycine, N-[(2ξ)-4,8-anhydro-2-[(3,7-anhydro-2-deoxy-D-glycero-D-manno-octonoyl)amino]-2,3-dideoxy-D-glycero-L-manno-nononoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184100-34-3 CAPLUS
CN Glycine, N-[(2ξ)-4,8-anhydro-2-[[3,7-anhydro-2-deoxy-4,5,6,8-tetrakis-O-(phenylmethyl)-D-glycero-L-manno-octonoyl]amino]-2,3-dideoxy-5,6,7,9-tetrakis-O-(phenylmethyl)-D-glycero-L-manno-nononoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184100-35-4 CAPLUS
CN Glycine, N-[(2ξ)-5,6,7,9-tetra-O-acetyl-4,8-anhydro-2,3-dideoxy-2-[(4,5,6,8-tetra-O-acetyl-3,7-anhydro-2-deoxy-D-glycero-L-manno-octonoyl)amino]-D-glycero-L-manno-nononoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:13473 CAPLUS

DN 122:56357
TI On the synthesis of C-glycosyl compounds containing double bonds without the use of protecting groups
AU Wulff, Guenter; Clarkson, Guy
CS Inst. Org. Chem. Makromol. Chem., Heinrich-Heine Univ., Duesseldorf, 40225, Germany
SO Carbohydrate Research (1994), 257(1), 81-95
CODEN: CRBRAT; ISSN: 0008-6215
DT Journal
LA English
OS CASREACT 122:56357
GI



I

AB A new range of C-glycosyl compds. carrying double bonds have been synthesized as potential monomers for the prepn. of polyvinyl-saccharides. The syntheses were performed without the use of protecting groups and mostly in water as solvent. The starting material was the easily accessible 5-β-D-glycopyranosyl-1,3-dimethylbarbituric acid sodium salt I (R = Na) (obtained from D-glucose and 1,3-dimethylbarbituric acid in water). The alkylation reaction of I (R = Na) at C-5 of the barbiturate moiety was studied in detail. It works well with benzylic bromides in Me2SO and with allylic or benzylic bromides by an ultrasound/phase transfer catalyst-promoted alkylation in water. The resulting 5,5-dialkylated barbiturates, e.g. I (R = CH2C6H4-R1, R1 = H, CH:CH2, CH2CH2Br; R = CH2CR2:CH2, R2 = H, Ph, CO2Me), undergo an unusually facile and specific cleavage of the barbituric ring, losing the c-2 carbonyl, to yield novel mols. with a diamide moiety.

IT 160055-68-5P 160055-69-6P 160055-70-9P
160055-71-0P 160055-72-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 160055-68-5 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-(phenylmethyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-69-6 CAPLUS
CN Propanediamide, 2-[(4-ethenylphenyl)methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-70-9 CAPLUS
CN Propanediamide, 5-[[4-(2-bromoethyl)phenyl]methyl]-N,N'-dimethyl-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-71-0 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-(2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160055-72-1 CAPLUS
CN Propanediamide, N,N'-dimethyl-2-(2-phenyl-2-propenyl)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:139581 CAPLUS
DN 98:139581
TI Effect of aryl substituents on the kinetics of inactivation of glycosidases by glycosylmethylaryltriazenes: examination of the suicide nature of these inactivations
AU Sinnott, Michael L.; Tzotzos, George T.; Marshall, Susan E.
CS Dep. Org. Chem., Univ. Bristol, Bristol, BS8 1TS, UK
SO Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1982), (12), 1665-70
CODEN: JCPKBH; ISSN: 0300-9580
DT Journal
LA English
AB The inactivation of the Mg2+-free form of the gene lacZ β-galactosidase of Escherichia coli at 25° by various [(β-D-galactopyranosyl)methyl]aryltriazenes resembles the spontaneous, rather than the acid-catalyzed, decomposition of alkylaryltriazenes in that both the maximum 1st-order rate constant, and the 2nd-order rate constant, are governed by a neg. β1g value at pH 7.0 and 8.0. Less extensive measurements for the β-xylosidase of Penicillium wortmanni and [(β-D-xylopyranosyl)methyl]aryltriazenes give a similar result. Although the decomposition of the 2-(β-D-galactopyranosyl)ethyl compds. in aqueous solution is 5- to 10-fold faster than their lower homologs, β-galactosidase inactivation is 3- to 13-fold slower. [(β-D-Galactopyranosyl)methyl](p-nitrophenyl)triazene does not inactivate the lectin, RCA ricin.
IT 85011-71-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and dehydration and catalytic reduction of)
RN 85011-71-8 CAPLUS
CN D-glycero-L-manno-Octonamide, 3,7-anhydro-2-deoxy-, 4,5,6,8-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> dis hist

     (FILE 'HOME' ENTERED AT 10:30:14 ON 30 JAN 2007)

     FILE 'REGISTRY' ENTERED AT 10:30:29 ON 30 JAN 2007
L1             STRUCTURE UPLOADED
L2            23 S L1 SSS SAM
L3           450 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:31:58 ON 30 JAN 2007
L4             0 S L3 AND (GEM(A)DIFLUORO)
L5             0 S L3 AND DIFLUORO
L6             1 S L3 AND ZINC
L7             0 S L3 AND REFORMATSKY
L8            44 S L3 AND (PROCESS OR PREPARA?)
L9             2 S L8 AND CARBONYL
L10            0 S L8 AND (CARBONYL(W)ADDITION)
```